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INTRODUCTION
1INTRODUCTION
Renal transplantation is currently the preferred treatment modality for
virtually all suitable candidates with end-stage renal disease. Compared with
dialysis, kidney transplantation improves both patient survival and quality of
life. Nonetheless, post transplant cardiac complications are associated with
increased morbidity and mortality after renal transplantation. When compared
with the general population, cardiovascular mortality in transplant recipients
is increased by nearly 10-fold among patients within the age range of 35 and
44 and at least doubled among those between the ages of 55 and 64. Although
renal transplantation ameliorates cardiovascular disease risk factors by
restoring renal function, it introduces new cardiovascular risks derived, in
part, from immunosuppressive medications.
AIM  OF  THE STUDY
2AIM OF THE STUDY
To analyze the risk factors for cardiovascular disease in the renal
transplant recipients
REVIEW  OF  LITERATURE
3REVIEW OF THE LITERATURE
Successful kidney transplantation has been shown repeatedly to be
associated with a reduction in mortality compared with dialysis. Studies
suggest that this effect largely may be the result of the reduction in
cardiovascular disease(CVD) associated with the improvement in renal
function. In a retrospective analysis of the United States Renal Data System
data consisting of more than 60,000 adult primary kidney transplant recipients
transplanted between 1995 to 2000 and more than 66,000 adult wait-listed
patients over the same time period, Meier-Kriesche et al1 showed a
progressive decrease in cardiovascular death rates by renal transplant vintage
for diabetic and nondiabetic recipients of both living- and deceased-donor
transplants. Although the CVD death rates among transplant recipients were
expectedly higher in the early postoperative period, they decreased
significantly by 3 months post transplant. On long-term follow-up evaluation,
although there seemed to be a modest increase in CVD death rates in the
second transplant year, the rates actually remained low even among high
CVD risk groups such as those with end-stage renal disease secondary to
diabetes mellitus or hypertension. This finding likely reflects the impact of
deteriorating transplant function on CVD death rates and is consistent with
the relationship between declining renal function and CVD risk observed in
non transplant chronic kidney disease2.Yet despite the well-established
survival advantage of transplantation over dialysis, CVD death has emerged
4as the most frequent cause of late graft loss. Recognition of CVD risk factors
and aggressive management of CVD risk factors should begin in the early
posttransplant period and should remain an integral part of long-term care in
renal transplant recipients.
CARDIOVASCULAR RISK FACTORS IN THE RECIPIENTS OF
RENAL TRANSPLANTS
Although all the determinants of enhanced CVD risks in renal
transplant recipients have not been well defined, both conventional and
unconventional risk factors have been suggested to be contributory. The
former risks include diabetes mellitus, hypertension, dyslipidemia, obesity,
smoking, and family history. The latter risks include pre-existing left
ventricular hypertrophy, coronary artery vascular calcification, impaired
allograft function, proteinuria, anemia, acute rejection episodes,
hyperhomocysteinemia, and inflammatory cytokines3,4. More recently, CD4
lymphopenia and cytomegalovirus (CMV) infection also has been suggested
to be associated with cardiac complications and atherosclerosis5,6,7. Selected
CVD risks are discussed here.
5Cardiovascular Risk Factors8
Major Risk Factors for Coronary Heart Disease in ATP III Guidelines
? Cigarette smoking
? Hypertension (ie, blood pressure >140/90 mm Hg or on
antihypertensive medication)
? High LDL cholesterol (ie, >159 mg/dL)
? Low HDL cholesterol (ie, <40 mg/dL)
? Family history of premature coronary heart disease (ie, <55years of
age in male first-degree relative or <65 years of agein female first-
degree relative)
? Age (men >45 years and women >55 years)
? Diabetes
Predisposing Risk Factors
? Obesity (ie, body mass index >30 kg/m2)
? Abdominal obesity (ie, waist circumference >102 cm, or 40in, for men
and >88 cm, or 35 in, for women)
? Physical inactivity
? Family history of premature coronary heart disease
6? Ethnic characteristics
? Psychosocial factors
? Nontraditional Biomarkers
? Elevated serum triglycerides
? Small LDL particles
? Elevated serum homocysteine
? Elevated serum lipoprotein(a)
? Prothrombotic factors (eg, fibrinogen)
? Inflammatory markers (eg, C-reactive protein, IL-6, CMV)
? B-type natriuretic peptide/N-terminal pro-atrial natriureticpeptide
? Aldosterone
Risk Factors Associated with Kidney Disease or Transplant
? Immunosuppressive agents
? Graft failure
? Graft dysfunction (elevated homocysteinemia, proteinuria, predisposition to
vascular calcification)
? Anaemia
7Risk factors for posttransplant cardiovascular disease
Risk Factor Strength of Evidence
Pretransplant cardiovascular disease ++++
Diabetes(includingposttransplant
diabetes)
++++
Cigarette smoking +++
Hyperlipidemia +++
Hypertension ++
Platelet and coagulation
abnormalities
++
Allograft dysfunction/rejection ++
Hypoalbuminemia ++
Erythrocytosis +
Oxygen free radicals +
Infections +
Increased homocysteine +
The determinants that lead to atherosclerosis in renal transplant
recipients are similar to those in the general population9-13
Risk factors for coronary heart disease after renal transplantation were
investigated in a report of 403 patients who received 464 kidney transplants
8during a 10-year period14. New atherosclerotic complications developed in 16
percent of patients. After accounting for pre-transplant vascular disease,
multivariate analysis revealed that the following risk factors were
independently associated with post-transplant atherosclerotic cardiovascular
disease: Increasing patient age, Diabetesmellitus, Male gender, Cigarette
smoking, Hypertension, Elevated serum cholesterol
Similar findings were observed in other studies13,15,16 including a
retrospective analysis of the placebo arm of the Assessment of LEscol in
Renal Transplantation (ALERT) study15.
 In multivariate analysis, independent risk factors for myocardial
infarction, cardiac death, and noncardiac death were preexisting coronary
heart disease (hazard ratio, 3.69), total cholesterol level (HR, 1.55 per 50
mg/dL), and prior acute rejection (HR, 1.58). Age, diabetes,  and elevated
serum creatinine levels were independent risk factors for cardiac death.
Other possible risk factors include hyperhomocysteinemia, elevated
levels of lipoprotein(a), elevated C-reactive protein and interleukin-6 levels,
proteinuria, allograft loss, obesity, and rejection17-22.
Prior to transplantation, most renal allograft recipients are uremic for
months or years. One of the features of this syndrome is accelerated
atherogenesis. The atherogenic factors contributing to this process prior to
transplantation may include hyperhomocysteinemia, hyperfibrinogenemia,
increased calcium ingestion, abnormalities of mineral metabolism,
9dyslipidemia, and modification of low-density lipoproteins (LDL) by
advanced glycosylation end-products (AGE), particularly in diabetics23-25.In
studies evaluating risk factors for post-transplant cardiovascular disease, pre-
transplant cardiovascular disease is among the most important
determinants14,2
SYSTEMIC HYPERTENSION
Hypertension is an independent risk factor for allograft failure and
mortality and is present in 50% to 90% of renal transplant recipients27,28.The
wide range in the frequency may reflect the variable definitions of
hypertension, donor source, immunosuppressive medications, time
posttransplantation, and level of allograft function. Systolic blood pressure
(BP) is highest immediately after transplantation and declines during the first
year27.
The contributory role of calcineurin inhibitors and glucocorticoids in
the development of posttransplant hypertension has been well established. In
a large randomized trial consisting of more than 400 patients randomized to
remain on sirolimus-cyclosporine-steroid (sirolimus-cyclosporine-steroid) or
to have cyclosporine withdrawn (sirolimus-steroid) at 3 months, systolic and
diastolic BP were significantly lower in the sirolimus-steroid compared with
the sirolimus-cyclosporine-steroid groups at the 36-month follow-up
evaluation (systolicBP, 131.3 versus 140.1 mm Hg, respectively, and diastolic
BP, 76.3 versus 81.2 mm Hg, respectively). Moreover, this difference was
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observed despite significantly less use of antihypertensive medication in the
sirolimus-steroid group30.A 3-year observational follow-up evaluation of a
European, multicenter, randomized, clinical trial comparing triple therapywith
tacrolimus, steroids, and mycophenolate mofetil (MMF) with withdrawal of
either steroids or MMF at 3 months after renal transplantation showed that
steroid withdrawal was advantageous in reducing hypertension,
hyperlipidemia, and diabetes mellitus31.The mean systolic BP was lower in
the steroid-stop group compared with the steroid maintenance groups (steroid
stop, 133.6 mm Hg; triple therapy, 136.2 mm Hg; MMF stop, 139.8 mm Hg).
The mean diastolic BP was similar in all groups. Renal function was
maintained in all groups, and patient and graft survival at 3 years were not
compromised by withdrawal of concomitant immunosuppression at 3 months
from a tacrolimus-based regimen.
The results of the Collaborative Transplant Study registry suggest that
BP control after transplantation is suboptimal. Management of posttransplant
hypertension should include attempts to identify and treat the underlying
cause, lifestyle modifications, and treatment of associated cardiovascular risk
factors. Lifestyle modifications should be similar to those used in the
nontransplant population. Potassium-based salt substitutes must be used with
caution or should be avoided because of the high incidence of hyperkalemia
among patients receiving cyclosporine or tacrolimus immunosuppression.
  There is a paucity of controlled clinical trials to determine the
superiority of one class of antihypertensive agents over the other in the
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transplant setting. In general, there are no absolute contraindications to the
use of any antihypertensive agent in renal transplant recipients. All classes of
antihypertensives have been used in various combinations with good results.
Nondihydropyridine calcium channel blockers and diuretics are used
frequently in the early posttransplant period, the former because of their
beneficial effect on renal hemodynamics and the latter because of their ability
to eliminate salt and water in these subjects who frequently are volume
expanded. In a single-center retrospective study to identify ischemic heart
disease risk after renal transplantation, Kasiske et al32 unexpectedly found an
association between the use of dihydropyridine calcium channel antagonists
and an increased risk of ischemic heart disease. Of interest, the use of
dihydropyridine calcium channel blockers in proteinuric chronic kidney
disease patients also has been shown to be associated with an increased risk of
renal disease progression and death, except when used in conjunction with
angiotensin II blockade therapy.9,33-35.
Although the mechanism(s) for the potential adverse effects of
dihydropyridine calcium channel blockers on the cardiovascular risk profile is
unclear, the use of amlodipine has been reported to be associated with
increased catecholamine levels36.Although further recommendations await
results of large, ongoing, randomized, controlled trials in the general
population, monotherapy with dihydropyridine calcium channel antagonists
should be used with caution.
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 The use of angiotensin converting enzyme inhibitor (ACE-I) and
angiotensin receptor blocker (ARB) alone or in combination has gained
increasing popularity because of their safety, efficacy, and well-established
renoprotective, antiproteinuric, and cardioprotective effects. Nonetheless, an
increase in serum creatinine level (ie, ?30% above baseline) associated with
their use should alert the clinician of possible transplant renal artery stenosis.
Caution should be exercised when used with diuretics because ACE-I or ARB
may potentiate volume depletion induced renal hypoperfusion. In patients
with slow or delayed graft function, ACE-I and ARB generally are not
recommended until allograft function has recovered.Mild to moderate renal
allograft dysfunction, however, does not exclude their use if serum potassium
and creatinine levels can be monitored closely.
Betablockers should be considered in patients with known coronary
artery disease or other atherosclerotic vascular disease whereas alpha2
blockers may be beneficial in patients with benign prostatic hypertrophy and
neurogenic bladder. Symptomatic bradycardia and blunting of hypoglycemic
unawareness occasionally may limit the use of the former. Although
aggressive blood pressure control is vital in reducing cardiovascular
morbidities and mortalities as well as improving graft survival, this is not
recommended in the early perioperative period because of the risk of
precipitating acute tubular necrosis and/or graft thrombosis.
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NEWONSET DIABETESMELLITUSAFTERTRANSPLANTATION
New-onset diabetes mellitus after transplantation (NODAT) is a well-
known complication after solid-organ transplantation and has been reported to
occur in 4% to 25% of renal transplant recipients. The variation in the
reported incidence may be owing to the lack of a universal agreement on the
definition of NODAT, the difference in the duration of follow-up evaluation,
and the presence of both modifiable and nonmodifiable risks factors. Kidney
transplant recipients who developed NODAT are at 2- to 3- fold increased
risk of fatal and nonfatal CVD events.9
Potential Risk Factors for NODAT
? African American and Hispanic ethnicities
? Obesity defined as a body mass index of >30 kg/m2
? Increasing age >40 years
? Male gender
? Family history of diabetes among first-degree relatives
? Impaired glucose tolerance before transplantation
? Recipients of deceased donor kidneys
? Hypertriglyceridemia
? Hypertension
? Hepatitis C and CMV infection
? Corticosteroids, tacrolimus, cyclosporine and Sirolimus
14
? The presence of certain HLA antigens such as A30, B27, and B42
? Increasing HLA mismatches
? Acute rejection history
? Male donor
The antimetabolites azathioprine and MMF have not been shown to be
diabetogenic. On the contrary, the concomitant use of MMF has been
suggested to mitigate the diabetogenic effect of tacrolimus.37It is conceivable
that the use of azathioprine or MMF allows clinicians to use lower doses of
other diabetogenic immunosuppressive medications. Early clinical trials have
suggested that sirolimus is devoid of a diabetogenic effect. However, recent
studies in animal models and in recipients of renal transplants have suggested
that sirolimus is associated with reduced insulin sensitivity and a defect in the
compensatory ?cell response.38,39 Studies in diabetic mice transplanted with
islet cells have suggested that sirolimus is associated with reduced islet
engraftment and impaired betacell function in transplants.39
The management of NODAT should follow the conventional approach
for patients with type 2 diabetes mellitus as recommended by many clinical
guidelines established by well recognized organizations including the
American Diabetes Association Further intervention may include adjustment
or modification in immunosuppressive medications and pharmacologic
therapy to achieve a target hemoglobin A1C level of less than 6.5%.
Corticosteroid dose reduction has been shown to improve glucose tolerance
15
significantly during the first year after transplantation.37 However, any dose
reduction should be weighed against the risk of acute rejection. A steroid-
sparing regimen or steroid avoidance protocol should be tailored to each
individual patient. Tacrolimus to cyclosporine conversion therapy in patients
who fail to achieve target glycemic control or in those with difficult to control
diabetes has yielded variable results.
When lifestyle modification fails to achieve adequate glycemic control,
medical intervention is recommended. Orally administered agents can be used
either alone or in combination with other oral agents or insulin. Although oral
hypoglycemic agents may be effective in many patients with corticosteroid,
cyclosporine, or tacrolimus induced NODAT, insulin therapy may be
necessary in up to 40% of patients 40 particularly in the early posttransplant
period.
The choice of pharmacologic therapy is based on the potential
advantages and disadvantages associated with the different classes of oral
agents. Although metformin (a biguanide derivative) is the preferred agent for
overweight patients, its use should be avoided in patients with impaired
allograft function because of the possibility of lactic acidosis. Care also
should be taken when the sulfonylurea derivatives are prescribed to patients
with impaired allograft function or to elderly patients because of the increased
risk of hypoglycemia. In general, it is best to start with a low dose and titrate
upward every 1 to 2 weeks. The nonsulfonylureas meglitinides are insulin
secretagogues with a mechanism of action similar to that of the sulfonylureas.
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Nonetheless, they have a more rapid onset and shorter duration of action and
seemingly lower risks of hypoglycemia and the amount of weight gain.41
These agents therefore are best suited for patients whose food intake is erratic,
elderly patients, and patients with impaired graft function. They are best taken
before meals and the dose may be omitted if a meal is skipped.
The thiazolidinedione derivatives are insulin sensitizers that may allow
for a reduction in insulin requirement. Potential adverse effects of these
agents include weight gain, peripheral edema, anemia, pulmonary edema, and
congestive heart failure. The incidence of peripheral edema is increased when
thiazolidinedione derivatives are used in combination therapy with insulin.
.Drug interactions also should be considered carefully.
 The meglitinide derivatives repaglinide and to a lesser extent
nateglinide are metabolized through the cytochrome p450 isozyme CYP 3A4,
and the glucose level should be monitored closely when the patient also
receives a strong inhibitor (eg, cyclosporine, gemfibrozil, or the azole
antifungal) or inducer (eg, rifampin, carbamazepine, phenytoin, or St John’s
wort) of the CYP 3A4 system.41 The use of gemfibrozil, a CYP 3A4 inhibitor,
and repaglinide combination therapy has been shown to dramatically increase
the action of the latter, resulting in prolonged hypoglycemia. Co-
administration of cyclosporine and repaglinide also has been shown to
enhance the blood glucose–lowering effect of repaglinide and increase the
risk of hypoglycemia.42In contrast, rifampin, a strong inducer of CYP 3A4,
considerably decreases the plasma concentration of repaglinide and also
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reduces its effects.43Although tacrolimus also is metabolized via the CYP 3A4
system and should therefore be susceptible to many drug interactions similar
to those of cyclosporine, these interactions are not as well documented.
Monitoring of patients with posttransplant diabetes mellitus should include
measuring hemoglobin A1C level every 3 months, and screening for diabetic
complications including microalbuminuria, regular ophthalmologic
examinations, and regular foot care. In addition, the fasting lipid profile
should be measured annually. In transplant recipients with multiple CVD risk
factors, more frequent monitoring of the lipid profile should be performed at
the discretion of the clinicians.
POST TRANSPLANT DYSLIPIDEMIA
Dyslipidemia is a common occurrence after transplantation. The
hyperlipemic effect of immunosuppressive agents including corticosteroids,
cyclosporine, tacrolimus, and sirolimus has been well documented. Although
tacrolimus-based therapy has been suggested to be associated with better lipid
profiles than cyclosporine-based therapy, sirolimus has been shown to be
associated with a significantly greater incidence and severity of dyslipidemia
than cyclosporine-based therapy, including higher total cholesterol and
triglyceride levels.
Causative Factors for Posttransplant Dyslipidemia
? Sirolimus, corticosteroids, cyclosporine, and tacrolimus
? Age
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? Diet
? Rapid weight gain
? Hyperinsulinemia
? Pre-existing hypercholesterolemia
? Allograft dysfunction
? Proteinuria
? betablockers and diuretic therapy
Although hyperlipidemia often improves within the first 6 months after
transplantation as the doses of prednisone, cyclosporine/tacrolimus, or
sirolimus are reduced, total and low-density lipoprotein (LDL) cholesterol
goals as defined by the National Cholesterol Education Program guidelines
usually are not achieved and treatment frequently is required. Management of
hyperlipidemia includes therapeutic lifestyle changes and pharmacotherapy
Statins or the hydroxyl glutaryl (HMG)-CoA reductase inhibitors are the most
widely used lipid-lowering agents in both the nontransplant and transplant
settings. The clinical benefits of statins have been shown in several large
randomized  controlled trials including the Heart Protection Study and the
Lescol Intervention Prevention Study44,45.
           The Heart Protection Study, the largest study to date, randomized more
than 20,000 individuals in the United Kingdom aged 40 to 80 years with total
cholesterol levels of greater than 135 mg/dL to receive either simvastatin (40
mg/day) or placebo. At the 5.5-year follow-up evaluation there was a 12%
19
reduction in total mortality, a 17% reduction in vascular mortality, a 24%
reduction in CVD events, a 27% reduction in strokes, and a 16% reduction in
noncoronary revascularizations44. The study further revealed that statin
therapy was beneficial in reducing major vascular events independent of
baseline LDL in patients with known coronary artery disease, cerebrovascular
disease, peripheral vascular disease, diabetes mellitus, or hypertension.
The beneficial effect of statins was greatest in the lowest LDL
subgroups (LDL < 60). Whether this effect can be extrapolated to renal
transplant recipients awaits further studies. Results of the Assessment of
Lescol in Renal Transplantation study revealed that treatment of renal
transplant recipients with fluvastatin over a 5- to 6-year period significantly
and safely reduced LDL cholesterol levels. The incidence of major adverse
cardiac events also was shown to be reduced, albeit not statistically
significant. However, further analysis showed a beneficial effect of early
initiation of fluvastatin on outcome the earlier the initiation of therapy, the
greater the reduction in cardiac events. For patients initiated on therapy within
the first 4years posttransplant, there was a risk reduction of 64% compared
with 19% for patients initiated on therapy after 10 years.
No statin effect on graft loss or on doubling of serum creatinine level
was observed46-48.This finding contrasts with that of Masterson et al49, who
found better renal function at 12 months posttransplant in recipients who
received statins compared with those who were not on statin therapy .Despite
the well-established efficacy and safety of the use of statins in transplant
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recipients clinicians should remain vigilant to the potential drug-drug
interactions in transplant patients, who often require multiple medications.
The use of statins in the presence of calcineurin inhibitors, particularly
cyclosporine, often results in a several-fold increase in statin blood level and
an increased risk for myopathy and rhabdomyolysis50.Cyclosporine increases
plasma exposure to fluvastatin by approximately 2-fold, simvastatin (20
mg/day) by 3-fold, atorvastatin by approximately 6-fold, pravastatin by 5- to
23-fold, and lovastatin by up to 20-fold. Approximate therapeutic
equivalencies are achieved by 10 mg of atorvastatin, 20 mg of simvastatin, 40
mg of pravastatin, 40 mg of lovastatin, and 80 mg of fluvastatin. At these
doses, the LDL cholesterol decrease is approximately 34%, with very little
change in highdensity lipoprotein levels50. In addition to their lipid-lowering
effect, statins may offer protection against CVD via their antiproliferative
properties and effects on the reduction of circulating endothelin-1, C-reactive
protein (CRP) levels, systolic and diastolic BP, and pulse pressure.
Other classes of lipid-lowering agents include fibric acid derivatives,
nicotinic acid, bile acid sequestrants, and the newer lipidlowering agent
ezetimibe. Ezetimibe and statin combination therapy can significantly
improve cholesterol control because of their complementary mechanism of
actions. Ezetimibe blocks intestinal absorption of dietary cholesterol and
related phytosterols whereas statin blocks hepatic cholesterol synthesis. The
currently available ezetimibe/simvastatin drug combination has been shown to
markedly reduce LDL-cholesterol (LDL-C) levels and has been suggested to
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represent a valuable option for the management of hyperlipidemia across
diverse patient populations51. In a cohort study consisting of 40 stable kidney
transplant recipients with hypercholesterolemia, 4 weeks of ezetimide therapy
significantly lowered total and LDL cholesterol levels52. In addition, the drug
was found to be more effective when used in combination with a statin. LDL
reduction was 24% ± 13% with ezetimide monotherapy versus 41% ± 13%
with the statin combination therapy. No significant adverse effects on serum
creatinine level, drug level, body weight, or liver function test results were
detected. It is likely that ezetimibe also can be used as adjunctive therapy with
other lipid-lowering agents in renal transplant recipients with poorly
controlled hyperlipidemia on statin monotherapy, although further
recommendations await further studies.
To date, no significant drug-to-drug interaction between ezetimibe and
calcineurin inhibitors or sirolimus has been reported. Severe
hypertriglyceridemia (TGL ? 500 mg/dL) has been encountered more
frequently since the introduction of sirolimus. Management includes sirolimus
dose reduction, addition of a fibric acid derivative or nicotinic acid, and, in
refractory cases, sirolimus to MMF or tacrolimus switch. Of the major fibric
acid medications (bezafibrate, ciprofibrate, fenofibrate, and gemfibrozil), the
first 3 have been reported to cause increases in the serum creatinine level in
cyclosporine-treated patients, as well as higher plasma homocysteine levels.
Although all fibrates in combinations with statins have been associated with
creatinine kinase increases with or without overt rhabdomyolysis and
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myopathy, gemfibrozil may have a greater risk for the development of
myopathy compared with bezafibrate or fenofibrate50.
Niacin monotherapy has not been reported to cause myopathy, but its
combined use with lovastatin, pravastatin, or simvastatin may be associated
with rhabdomyolysis. Bile acid sequestrants must be used with caution
because of their potential interference with the absorption of other
medications vital to the renal transplant recipients.
Suggested guidelines for the treatment of posttransplant dyslipidemia
includes all transplant recipients should be regarded as CHD risk equivalent.
Goals: LDL ? 100 mg/dL (optional ? 70 mg/dL), TGL ? 200 mg/dL, HDL ?
45 mg/dL. has been suggested for very high-risk patients (NCEP, ATP III
guidelines). Statins are the most effective drugs and should be the agents of
first choice. Start at low dose in patients on cyclosporine and tacrolimus.
Monitor for myositis and transaminitis, particularly in those receiving
combination therapy. Bile acid sequestrans should probably not be taken at
the same time as cyclosporine. Extreme caution should be used with statin
and fibrate combination therapy. Consider cholesterol absorption inhibitors in
patients intolerant to statins.
RENAL INSUFFICIENCY
Renal insufficiency in renal transplant patients is also a significant risk
factor for adverse cardiovascular outcomes53-55.Among nearly 60,000 patients
in one study, serum creatinine levels above 1.5 mg/dL (133 µmol/L) at one
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year post-transplant were significantly associated with an increased risk for
cardiovascular disease53.In a second study of almost 30,000 renal transplant
recipients, a decreased estimated glomerular filtration rate at one year post-
transplant correlated with increased risks of acute coronary syndrome and
heart failure54.Among over 1000 placebo-treated patients in the Assessment of
LEscol in Renal Transplantation (ALERT) trial, an increased serum creatinine
concentration, particularly higher than 2.3 mg/dL (200 micromol/L), was
strongly associated with an increased risk of adverse cardiac events and
cardiac death55,56.
OBESITY
Obesity trends in transplant recipients tend to mimic the general
population, 65 percent of whom are now defined as overweight (body mass
index [BMI] 25 to 29.9 kg/m2). In one study from the United Network for
Organ Sharing, approximately one-half of patients who underwent kidney
transplantation between 1997 and 1999 were obese (BMI 30 to 35) or
morbidly obese (BMI ?35)57.Among kidney transplant recipients, the
presence of obesity, particularly within the context of the metabolic
syndrome, also appears to be associated with an increased number of adverse
cardiovascular events. In one study of 337 renal transplant recipients, one-
third of whom had metabolic syndrome, 42 patients experienced an adverse
atherosclerotic event at one year post-transplant58
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Compared to those without metabolic syndrome, a significantly higher
incidence of such events was observed among patients with the syndrome (25
versus 7 percent).Obesity also increases the risk of heart failure and atrial
fibrillation. This was shown in a single center study in which the five-year
incidence of cardiac diagnoses increased from 9 to 30 percent as the BMI
quartiles increased from the lowest to highest59. This was largely due to
increases in the incidence of heart failure and atrial fibrillation.
HOMOCYSTEINE
 Homocysteine is a nonessential amino acid that is an intermediate in
the synthesis of cysteine and a precursor of the essential amino acid,
methionine. Since homocysteine is normally cleared by the kidneys, serum
concentrations are increased in chronic renal failure62,63.Another major cause
is an absolute or relative deficiency of vitamins B6, B12, and folate, all of
which are involved in methionine metabolism. A defect in the methylene
tetrahydrofolate reductase enzyme has also been causally associated with
hyperhomocysteinemia. The presence of elevated homocysteine levels in
peripheral venous blood has been identified as an independent risk factor for
ischemic heart disease and stroke in the general population, as well as being a
predictor of mortality in patients with coronary heart disease64,65.
In one prospective study of 207 stable patients, fasting mean total
homocysteine levels were significantly higher among patients who
experienced a cardiovascular event at follow-up of 21 months (32 versus 18
25
µmol/L for those without such an event)66.Among 733 kidney transplant
recipients during a six-year period, elevated homocysteine levels were
associated with 2.44 times the mortality risk of patients with normal levels
(hazards ratio 2.44, CI 95% 1.45-4.12)67.In patients with end-stage renal
disease, hyperhomocysteinemia is closely linked with decreased serum folate
and pyridoxine concentrations63. Serum homocysteine concentrations often
continue to rise after both renal and cardiac transplantation, independent of
renal function68-70.
In one series, serum concentrations of total homocysteine were
significantly higher in 120 renal transplant recipients than in 60 healthy
controls (mean 19.0 versus 11.6 µmol/L) or 53 patients with chronic renal
failure (mean 16.0 µmol/L)70 .  In this report, renal transplant recipients on
cyclosporine had significantly higher plasma homocysteine concentrations
than those not on cyclosporine. A similar role for cyclosporine was noted in
another series71.however, this association has not been confirmed in other
studies72.Effective reduction in serum homocysteine levels in renal transplant
recipients may be obtained with the administration of folic acid and vitamins
B6 and B1273.However, although hyperhomocysteinemia is an independent
risk factor for cerebrovascular, peripheral vascular, and coronary heart
disease, the effect of lowering homocysteine levels on cardiovascular risk in
renal transplant recipients has been unclear
The NIH has sponsored a multicenter randomized control trial
(FAVORIT: Folic Acid for Vascular Outcome Reduction In Transplantation),
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that has examined the effectiveness of B complex vitamin supplementation on
the cardiovascular outcomes in kidney transplant recipients. Preliminary
results presented in abstract form indicate that while homocysteine can be
effectively lowered in this patient population, no benefit was seen in terms of
lowering cardiovascular events or deaths.
FRAMINGHAM RISK SCORE
The Framingham risk score has a modest ability to predict
cardiovascular outcomes among kidney transplant patients. A prospective
cohort evaluation of 540 patients followed for 4.7 years found that the ratio of
observed-to-predicted cardiac events was 1.64-fold higher for the group and
2.74-fold higher in those ages 45 to 60 with prior cardiac disease or diabetes
mellitus74.
The Framingham Risk Score is used to estimate the 10-
year cardiovascular risk of an individual. The Framingham Risk Score is
based on data obtained from the Framingham Heart Study. There are two
Framingham Risk Scores, one for men and one for women.
The Framingham Risk Score is one of a number of scoring systems
used to determine an individual's chances of developing cardiovascular
disease. This means either coronary heart disease or stroke. A number of these
scoring systems are available online75.Cardiovascular risk scoring systems
give a best estimate of the probability that a person will develop
cardiovascular disease within the next 5 or 10 years. Because they give an
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indication of who is most likely to develop cardiovascular disease they also
indicate who is most likely to benefit from prevention. For this reason
cardiovascular risk scores are used to determine who should be offered
preventive drugs such as drugs to lower blood pressure and drugs to lower
cholesterol levels.
Because the Framingham Risk Score (or another appropriate scoring
system) give a good indication of the likely benefits of prevention, they are
useful for both the individual patient and for the clinician in helping decide
whether lifestyle modification and preventive medical treatment, and for
patient education, by identifying men and women at increased risk for future
cardiovascular events76.The CHD risk at 10 years in percent can be calculated
with the help of the Framingham Risk Score. Individuals with low risk have
10% or less CHD risk at 10 years, with intermediate risk 10-20%, and
with high risk 20% or more. However it should be remembered that these
categorisations are arbitrary.
A more useful metric is to consider the effects of treatment. If 100
persons have a 20% ten-year risk of cardiovascular disease it means that 20 of
these 100 individuals will develop cardiovascular disease (coronary heart
disease or stroke) in the next 10 years. Eighty of them will not develop
cardiovascular disease in the next 10 years. If they were to take a combination
of treatments (for example drugs to lower cholesterol levels plus drugs to
lower blood pressure) that reduced their risk of cardiovascular disease by half
it means that 10 of these 100 individuals would develop cardiovascular
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disease in the next 10 years: 90 of them would not develop cardiovascular
disease. This means that 10 of these individuals would have avoided
cardiovascular disease by taking treatment for 10 years; 10 would get
cardiovascular disease whether or not they took treatment; and 80 would not
have got cardiovascular disease whether or not they took treatment
INFLAMMATION AND OXIDATIVE STRESS
Inflammation and oxidative stress, which are prevalent in patients with
CKD, are not controlled effectively by dialysis. Simmons et al3 have shown
that pretransplant levels of the proinflammatory proteins interleukin-6, tumor
necrosis factor-?, and CRP, as well as the oxidative stress markers plasma
protein carbonyls and F2-isoprostanes, were increased significantly in CKD
patients compared with healthy control subjects. After a successful kidney
transplant, there was a rapid and sustained decline in all of these biomarkers,
reaching levels of those of controls by 2 months posttransplant.
In a prospective study to determine the incidence and risk factors for
ischemic heart disease in renal transplant recipients who were free of vascular
disease at enrollment, coronary events were recorded in 7.8% of 344
consecutive renal transplant recipients at a mean follow up period of 72 ± 14
months. In addition to traditional Framingham risk factors, CRP level  and
hyperhomocysteinemia were found to be independent risk factors for
ischemic heart disease events77. Increased CRP and other inflammatory
markers also have been shown to be associated with an increased risk of all-
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cause mortality in renal transplant recipients. In a single-center prospective
study consisting of more than 400 consecutive kidney transplant recipients
followed up for a median of 7.8 years, Winkelmayer et al78 showed that
patients with a CRP of 0.5 mg/dL or higher had a 53% higher mortality risk
compared with patients whose CRP was below that threshold [hazard ratio
(HR) = 1.53; 95% confidence interval, 1.01-2.31; P = .04]. No associations
between CRP and the risk of kidney allograft loss were detected. Recent
studies have established a link between inflammation, atherosclerosis, and
other manifestations of cardiovascular disease.
Hansson79illustrated the similarities between the role of T-cell
activation on plaque inflammation and on the alloimmune response. It is
conceivable that the dramatic reduction in CVD mortality posttransplant
compared with remaining on dialysis is, in part, related to the use of
immunosuppressive agents that also are antiinflammatory. The putative role
of inflammation in the development of pretransplant and posttransplant
morbidity and mortality raises intriguing therapeutic options. Grotz et al80
hypothesized that aspirin protects allograft function and survival in the
context of chronic renal allograft dysfunction because of the similarities
between the inflammatory mechanisms underlying atherogenesis and chronic
allograft nephropathy. In a retrospective multivariate analysis performed to
assess the effect of low-dose aspirin treatment (100 mg/d) on allograft
function and survival, the Grotz et al80 found that low-dose aspirin
substantially improved median allograft survival time compared with no
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aspirin treatment (low-dose aspirin versus no aspirin, 13.8 ± 2.6 years [n =
205] versus 7.8 ± 0.3 years [n =625], respectively; adjusted relative risk,
0.443; P =0 .0001).
Renal allograft function was better preserved in aspirin treated patients,
who displayed a slower increase of serum creatinine level and less proteinuria
and hematuria during the observation period. The investigators suggested that
aspirin should be considered as part of the long-term posttransplant treatment
regimen. The failed or failing kidney transplant also has been suggested to be
a potential source of chronic inflammation, which contributes to higher
morbidity and mortality rates among patients who returned to hemodialysis
after failure of their kidney transplant compared with nontransplanted dialysis
patients. Lopez-Gomez et al 81 found that hemodialysis patients with a failed
kidney transplant in situ commonly suffered from a chronic inflammatory
state and that transplant nephrectomy was associated with amelioration of
markers of chronic inflammation, including improvement in serum albumin
level, prealbumin level, ferritin level, fibrinogen level, CRP level, erythrocyte
sedimentation rate, and erythropoietin resistance index. Transplant
nephrectomy should be considered in patients with failed kidney transplants,
particularly if they show clinical evidence of a chronic inflammatory state.
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PROTEINURIA
Proteinuria has been reported to occur in 9% to 40% of kidney
transplant recipients with a functioning allograft 82.As in the nontransplant
setting, posttransplantation proteinuria has been shown to be an independent
risk factor for CVD. In a retrospective study consisting of more than 500
Caucasian patients who received a deceased-donor renal transplant and had a
functioning allograft for longer than a year, Fernandez- Fresnedo et al 83
found that compared with no proteinuria, the presence of persistent
proteinuria (defined as urine protein excretion greater than 0.5 g/d for more
than 6 months; mean follow-up period, 6.41± 3.6 y) was associated with
increased mortality and graft loss (relative risk of death and graft loss [RR],
1.92 and 4.18, respectively), and a higher incidence of CVD (RR, 2.45).
Roodnat et al84  reported a nearly 2-fold risk of death in renal
transplant recipients with a functioning allograft and proteinuria at 1 year
compared with those without proteinuria. The literature on the link between
proteinuria and increased CVD and related death, and its negative impact on
patient and kidney allograft survival, has been increasingly recognized. It is
suggested that proteinuria is a biomarker ofsystemic endothelial dysfunction
inherent to the atherosclerotic process 85. Unless contraindicated, ACE-I,
ARB, or both should be considered in transplant recipients with
microalbuminuria or overt proteinuria because of their well-established
renoprotective, antiproteinuric, and cardioprotective effects. Whether the
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development of proteinuria associated with sirolimus 86 adversely affects
CVD risks currently is unknown and warrants close monitoring
ANEMIA
Anemia after renal transplantation has a reported prevalence of 20% to
80% 87. The wide variation in the prevalence reported in part is owing to the
variable definitions of anemia, immunosuppressive medications, time post
transplantation, duration of follow-up evaluation, and level of allograft
function, among others. In a retrospective study consisting of 92 renal
transplant recipients with a functioning allograft at 1 year, post transplant
anemia, defined as a hemoglobin level of less than 13 g/dL for men and less
than 12 g/dL for women, was found in 35.5% and 25% of patients at months 6
and 12, respectively88.In a multivariate analysis, the independent predictive
factors of anemia at month 6 were erythropoietin level at day 0, cause of end-
stage renal disease (polycystic kidney disease versus others), post
transplantation recombinant erythropoietin therapy, hematocrit level at month
3, platelets at day 7, and sirolimus therapy. Delayed graft function, renal
function at month 12, and anemia at month 6 were independent risk factors
for the presence of persistent anemia at 1 year.
 In a retrospective study consisting of more than 200 transplant
recipients receiving sirolimus, nearly 60% were found to be anemic, a
frequency nearly twice that for patients receiving MMF89. It has been
suggested that sirolimus inhibits erythropoiesis at the level of the
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erythropoietin receptor. The binding of erythropoietin to its cytoplasmic
receptors leads to the activation of a cascade of phosphorylating enzymes
including phosphoinositide 3-kinase, an enzyme responsible for controlling
cell survival and cell-cycle progression in several cell lines including
erythroid precursors. Sirolimus blocks p70S6-kinase, an enzyme downstream
from phosphoinositide 3-kinase, and inhibits basal- as well as
erythropoietinstimulated proliferation. Sirolimus, however, does not interfere
with the maturation of the J2E erythroid cell line 90. Suggested causative
factors for posttransplant anemia include iron, folate, and B12 deficiency,
impaired allograft function, acute rejection epi sodes, recent infection, and
medications such as azathioprine, MMF, sirolimus, and ACE-I and ARB.
Anemia also has been reported to be more common in African American and
female transplant recipients. Similar to the general population and patients
with chronic kidney disease, it has shown that anemia adversely affects CVD
in kidney transplant recipients. In a multivariate analysis of more than 400
recipients of kidney alone or simultaneous kidney- pancreas transplants,
Djamali et al 91 found that diabetic transplant recipients with a hematocrit
level greater than 30% were less likely to suffer from a CVD event
(myocardial infarction, cardiovascular death, angina, and congestive heart
failure) in the first 6 posttransplant months compared with those with a
hematocrit level less than or equal to 30%.
In a retrospective study involving consecutive de novo MMF-treated
kidney recipients from the Hospital of the University of Pennsylvania
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between 1996 and 2002, Imoagene- Oyedeji et al 92 revealed that the cohort
with anemia at 12 months, defined as a hemoglobin level of less than 12 g/dL,
had inferior patient survival  and a higher proportion of cardiovascular deaths
(6.3% versus 2.2%) compared with the nonanemic patients.
In a study involving more than 400 kidney transplant recipients,
Winkelmayer et al93 failed to show an association between anemia defined as
a hemoglobin level less than 10 g/dL and mortality or graft loss. Among the
iron parameters, only the percentage of hypochromic red cells was associated
with greater all-cause mortality. The clinical significance and therapeutic
implications of these findings remain to be determined. Darbepoetin alfa is an
effective and safe alternative to recombinant human erythropoietin treatment
for anemic renal transplant recipients. However,it currently is not known
whether erythropoiesis-stimulating agents have a beneficial effect on CVD
risk factor reduction beyond correction of post transplant anemia alone.
Assessment of baseline iron stores at the time of transplantation may be
invaluable because iron deficiency is not uncommon in the dialysis
population. Profound iron deficiency should be treated with intravenous iron
as tolerated. Refractory or severe anemia mandates aggressive evaluation to
exclude the possibility of surgical postoperative bleeding, particularly in those
with a rapid decrease in hemoglobin and hematocrit levels. Other possibilities
include gastrointestinal bleed, tertiary hyperparathyroidism, underlying
inflammatory conditions, or parvovirus B19 infection. Erythropoietin-
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resistant anemia has been described in patients receiving sirolimus
immunosuppression.
HYPOALBUMINEMIA
Up to 70% of the dialysis patients have some element of malnutrition
and low serum albumin level is a predictor of mortality risk for ESRD
patients on dialysis. Approximately 10% of patients exhibit hypoalbuminemia
at 1 year and 20% at 10 years after transplantation. Low serum albumin levels
may be the result of decreased production and/or increased catabolism 94,95.
Increased urinary protein excretion, especially in patients with chronic
transplant nephropathy, may also result in low serum albumin levels. Chronic
allograft nephropathy with hypoalbuminemia is associated with decrease in
muscle mass, which is reflected in decreases in urinary creatinine excretion.
Corticosteroids accelerate the protein catabolic rate and frequently create
negative nitrogen balance. Studies by Hoy et al 96.have documented
significant increases in the protein catabolic rate, accompanied by decreases
in serum albumin levels, in the immediate posttransplant period. Even
maintenance low-dose corticosteroid therapy increases protein catabolism and
muscle wasting. Severe protein catabolism contributes to poor wound healing
and an increased susceptibility to infection97. Early nutritional support is
indicated in high-risk patients. Assessment of nutritional status by a renal
dietitian should be incorporated into the clinic visit. Serum albumin should be
monitored annually. Serum prealbumin levels should be measured if albumin
levels are low or if clinical findings suggest possible malnutrition. The degree
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of protein catabolism can be assessed by the measurement of urea nitrogen
appearance. A daily protein intake ranging from 0.55 to 1.0 g/kg has been
recommended for stable posttransplant patients.
LEFT VENTRICULAR HYPERTROPHY AND CARDIO VASCULAR
RISK
Left ventricular hypertrophy may be considered either a risk factor for
subsequent major cardiovascular events, or a cardiovascular disease itself.
Although this is still a topic for debate. LVH is present in 40–60% of renal
transplant recipients, and its persistence in the first year after renal
transplantation is associated with reduced patient survival 98. LVH has also
been shown to be the strongest predictor of all-cause mortality, together with
diabetes98. Left ventricular hypertrophy is inversely correlated with renal
function 99. Improved renal function following renal transplantation
ameliorates LVH; however, a degree of LVH is often still present in renal
transplant recipients and may be exacerbated as graft function declines100
.Renal dysfunction may increase LVH through hypertension,volume
expansion, hyperparathyroidism, and/or altered calcium-phosphate
homeostasis101.Preliminary results from a clinical trial examining the effects
of conversion from CNI to sirolimus showed a significant regression of LVH
in the majority of renal transplant patients at 1 year after conversion102 . This
regression in LVH occurs mainly by decreasing left ventricular wall
thickness, which suggests a nonhemodynamiceffect mechanism of sirolimus
of the left ventricular mass 102 .
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HYPERURICEMIA
Renal handling of uric acid is affected by the use of CsA leading to
higher serum urate levels in CsA-treated patients103,104,105. Asymptomatic
hyperuricemia occurs in 55% of patients receiving CsA and in 25% of those
taking azathioprine. There is no report of graft failure due to urate
nephropathy in the transplanted kidney. Crystal-induced erosive arthritis can
occur in these patients. Nonsteroidal anti-inflammatory agents should also be
avoided because of potential negative influence on renal hemodynamics and
the development of interstitial nephritis. Colchicine is the preferred treatment
if symptoms persist. Allopurinol, a xanthine oxidase inhibitor, should be
avoided in patients taking azathioprine. Concomitant administration of
allopurinol and azathioprine results in marrow suppression and a fourfold
increase in immunosuppression
POST TRANSPLANT ERYTHROCYTOSIS
An increased erythrocyte mass has been demonstrated in some 17% of
graft recipients106. Erythrocytosis, defined as a hematocrit greater than 52%,
most often occurs within the first year after transplantation and may be
associated with good allograft function, chronic rejection, transplant renal
artery stenosis107, hydronephrosis, native kidney and hepatic erythropoietin
production, and the use of androgenic steroids. In patients with good allograft
function, it is postulated that correction of the uremic milieu allows
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overzealous red blood cell production, because of a reset marrow response to
erythropoietin (EPO) 108,109.
 In patients with chronic rejection, renal artery stenosis, and
hydronephrosis, intrarenal hypoxemia may stimulate erythropoietin
production 110.In most cases, the precise etiology is uncertain, but studies on
erythropoietin levels after transplantation indicate that graft function restores
the hematopoietic response to normal. The phenomenon usually is self-
limited, lasting 3 to 12 months. Low doses of an ACE inhibitor (beginning
with 2.5 mg of enalapril per day or 12.5 mg of captopril twice a day) reduces
the hematocrit to normal or near normal levels. The effect begins within 6
weeks and is complete in 3 to 6 months.
 An association between the ACE inhibitor-induced reduction in
hematocrit and a fall in plasma EPO levels has been demonstrated in some
studies. Also compatible with an EPO-independent mechanism is the
observation that withdrawal of the ACE inhibitor results in a gradual rise in
hematocrit without a concurrent elevation in EPO levels. ACE inhibitors can
also induce anemia in some renal transplant recipients without erythrocytosis.
The mechanism of action is unclear. An alternative to ACE inhibition is
theophylline. Theophylline appears to act as an adenosine antagonist in this
setting, suggesting that adenosine facilitates both the release and perhaps the
bone marrow response to EPO 111-114. In severe cases (hematocrit >52%),
phlebotomy is indicated to prevent thromboembolic complications, which
may occur in as many as 20% of patients with erythrocytosis.
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CAROTID INTIMA MEDIA THICKNESS
Links between CIMT and coronary heart disease115 or stroke116 [14] are
well known. An association between carotid intima media thickness (CIMT)
and cardio-vascular risk factors has been demonstrated in several
epidemiological studies117-121. Ultrasound measurement of the two internal
layers of the carotid artery is a validatedtechnique122. IMT study has opened a
broad field in clinical research because it detects early arterial disease in
asymptomatic individuals and is significantly associated to a higher risk of
incident myocardial infarction and stroke123 . IMT measurements could
constitute an important tool to identify and target intermediate risk subjects in
preventive medicine. In this large cross-sectional study of 5199 subjects,
found that the Framingham score and CIMT values were significantly
correlated
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MATERIALS AND METHODS
Study place : Govt.Stanley Medical College & Hospital
Nephrology Department, Chennai
Study period : From October 2010 to November 2011
Study design : Retrospective Analytical study
Study population : Cadaver and Live related renal transplant
recipients(RTR)
EXCLUSION CRITERIA
• Less than one month post transplant
• Less than 18 years of age
• Death due to non cardiac causes during the study
• Graft dysfunction and on maintanance hemodialysis
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• Ethical Committee approval from Stanley Medical College, Chennai
was obtained for this study.
• All recipients were ABO compatible and cross-match negative and
they are followed up regularly in NEPHROLOGY TRANSPLANT
OPD.
• Recipients demographic factors like Age, Gender, Occupation,
Literacy were noted.
• Nature of donor, post transplant duration, graft function were noted.
• fasting blood samples were drawn to determine serum creatinine, Total
cholesterol, Triglycerides, LDL and HDL cholesterol and plasma
glucose concentrations.
• Blood pressure was reported as the average of three manual
measurements taken at 3-minutes intervals.
• Hypertension was defined by (i) the administration of antihypertensive
agents and/or a history of this disorder; (ii) a systolic blood pressure
more than 130 mmHg; or (iii) a diastolic blood pressure more than 80
mmHg.
• NODAT was defined as a fasting glucose of more than 126mg/dl on
two occasions at any time after transplantation or associated with use
of oral hypoglycemic agents and/or insulin, in patients with no prior
history of diabetes.
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• Weight was measured by the weighing machine which was daily
calibrated by a weight of 5 kg, with the subject in light clothing.
•  Height was measured by a scale fitted on the wall and the subject
standing without shoes. BMI was calculated by the formula weight in
kg / height in m2.
• Waist circumference was determined by using a non-stretchable
measuring tape midway between the iliac crest and costal margin.
•  2 hours post prandial Blood samples were taken to analyze sugar,
hemoglobin,  serum albumin,uricacid.
• Diagnosis of Metabolic Syndrome(MS) was made by The National
Cholesterol Education Program- Adult Treatment Panel III (NCEP
ATP III) criteria such as
(Subjects who had three or more of the risk factors were labelled as MS)
• Fasting blood glucose >110 mg/dl or use of antidiabetic
medication,
• Waist circumference >40inch for men and >35inch for women
• (iii)  SBP > 130 mmHg and DBP more than 85 mmHg or use of
antihypertensive medication,
• (iv) TGL >150mg/dl or specific treatment for this lipid
abnormality
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• (v) HDL — cholesterol level <40mg/dl in men or <50mg/dl in women
or specific treatment for this lipid abnormality,
• Routine urine investigation was done by dipstick method
• Hemoglobin less than 13.5gm/dl in males, less than 12gm/dl in females
considered as anaemia and more than 17gm/dl defined as post
transplant erythrocytosis
• Framingham risk score was determined by online
calculator(hp2010.nhlbihin.net/atpiii/calculator.asp)
• Average carotid intima media thickness was measured by ALOKA
ultra sonogram machine.
• Echocardiogram was done to analyze cardiac function, regional wall
motion abnormality, left ventricular hypertrophy and ejection fraction
STATISTICAL METHODOLOGY
The statistical analysis had been done by using SPSS (Statistical
Package on Social Science) version 15.0
The non-parametric model can be used to find out the relationship of
categorical variable.  One of the method was Pearson’s exact Chi-square.
Multi variate analysis was done by MULTIPLE LOGISTIC
REGRESSION ANALYSIS
RESULTS
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RESULTS
 Totally 170 recipients are on regular follow up in our department from
the period October 2010 to November 2011.
Patients who died in that period and those who are on irregular follow
up are excluded from the study
Total patients are divided into groups according to FRAMINGHAM
RISK SCORE to predict 10 year ABSOLUTE RISK of coronary heart disease
event.
 Recipients were fit into risk category of 1-3%, 3-5%, 5-8%, 8-10%
with prevalence of 80.6%, 11.8%, 4.7%, 2.9% respectively.
FRS NUMBER PERCENTAGE
1 – 3% 137 80.60%
3- 5% 20 11.80%
5- 8% 8 4.70%
8- 10% 5 2.90%
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The following recipient’s variables are compared with risk groups
1. Age
2. Sex
3. Donor type
4. Post transplant duration in months
5. Graft dysfunction
6. Body mass index
7.  New Onset Diabetes After Transplantation(NODAT)
8. Systemic hypertension
9. Total Cholesterol
10. HDL cholesterol
11. LDL cholesterol
12. Triglycerides
13. Immunosuppressive drugs
14. ECHO-cardiac function
15. ECHO-regional wall motion abnormality
16. ECHO-left ventricular hypertrophy
17. ECHO-ejection fraction
18. Urine routine
19. Hemoglobin
20. Serum albumin
21. Serum uricacid
22. Carotid intima media thickness
All the data are collected in the master sheet and statistically analyzed
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AGE(YEARS) NUMBER PERCENTAGE
<40 144 84.7%
>40 26 15.3%
AGE * FRS
variable PREVALANCE p-Value
FRSGroupAge in years
1-3% 3-5% 5-8% 8-10%
Below 40 78.9% 8.3% 2.8% 0%
Above 40 34.6% 30.8% 15.4% 19.2% 0.001
Increased recipient  age significantly associated with high cardiovascular risk
factor score, p- Value .001
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SEX NUMBER PERCENTAGE
MALE 124 72.94%
FEMALE 46 27.06%
SEX * FRS
variable PREVALENCE p-Value
FRSGroupSEX
1-3% 3-5% 5-8% 8-10%
MALE 79.8% 12.9% 4.0% 3.2%
FEMALE 82.6% 8.7% 6.5% 2.2% 0.893
There was no gender predisposition towards cardio vascular risks
p-Value 0.8
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DONOR NUMBER PERCENTAGE
LIVE 142 83.52%
CADAVER 28 16.48%
DONOR * FRS
variable PREVALENCE p-Value
FRSGroupDONOR
1-3% 3-5% 5-8% 8-10%
LIVE 83.1% 12.0% 2.8% 2.1%
CADAVER 67.8% 10.7% 14.3% 7.1%
0.026
Increased cardio vascular risk score associated with cadaveric graft recipients
which was statistically significant, p-Value 0.026
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POST TRANSPLANT
DURATION
NUMBER PERCENTAGE
<12 MONTHS 29 17.05%
13 – 24 MONTHS 32 18.82%
25 – 48 MONTHS 33 19.42%
>48 MONTHS 76 44.71%
POST TRANSPLANT DURATION* FRS
variable PREVALENCE p-Value
FRSGroupPost
transplant
duration in
months 1-3% 3-5% 5-8% 8-10%
<12 86.2% 10.3% 3.4% 0 %
13-24 71.9% 15.6% 9.4% 3.1%
25-48 78.7% 9.1% 9.1% 3.0%
>48 82.9% 11.8% 1.3% 3.9%
0.273
Duration of post transplant period was  not significantly associated with
Cardiovascular risk score
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GRAFT NUMBER PERCENTAGE
DYSFUNCTION 88 51.75%
NORMAL
FUNCTION
82 48.25%
GRAFT DYSFUNCTION * FRS
variable PREVALENCE p-Value
FRSGroupGRAFT
DYSFUNCTION
1-3% 3-5% 5-8% 8-10%
NO 83.0% 9.8% 6.1% 1.2%
YES 78.4% 13.6% 3.4% 4.5%
0.458
Higher risk value for graft dysfunction recipients
Influence of graft dysfunction over cardio vascular risk score- not
significant
p-Value 0.458
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BMI NUMBER PERCENTAGE
UNDERWEIGHT 28 16.47%
NORMAL WEIGHT 105 61.76%
OVERWEIGHT 30 17.64%
OBESE 7 4.13%
BODY MASS INDEX * FRS
variable PREVALENCE p-Value
FRSGroupBMI
1-3% 3-5% 5-8% 8-10%
UNDER
WEIGHT 82.1% 7.1% 10.7% 0 %
NORMAL 81.9% 10.5% 2.9% 4.8%
OVER
WEIGHT 76.6% 20.0% 3.3% 0%
OBESEITY I 71.4% 14.3% 14.3% 0%
0.120
Influence of BMI over cardio vascular risk score not statistically significant
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METABOLIC
SYNDROME NUMBER PERCENTAGE
NO 117 68.82%
YES 53 31.18%
METABOLIC SYNDROME * FRS
variable PREVALENCE p-Value
FRSGroupMETABOLIC
SYNDROME
1-3% 3-5% 5-8% 8-10%
NO 89.7% 9.4% 0% 0.9%
YES 60.4% 17.0% 15.1% 7.5%
0.001
Presence of metabolic syndrome  had significant association with high  cardio
vascular risk score
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NODAT NUMBER PERCENTAGE
NO 136 79.42%
YES 33 19.41%
PRE TRANSPLANT
DM
2 1.17%
NEW ONSET DIABETES AFTER TRASPLANTATION * FRS
variable PREVALENCE p-Value
FRSGroupNODAT
1-3% 3-5% 5-8% 8-10%
NO 90.3% 8.1% 0.7% 0.7%
YES 42.5% 27.3% 18.2% 12.1%
Pre transplant
DM 50% 0% 50% 0%
0.001
NODAT had significant correlation with cardio vascular risk score
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SHT NUMBER PERCENTAGE
NO 34 20%
YES 136 80%
SYSTEMIC HYPERTENSION * FRS
variable PREVALENCE p-Value
FRSGroupSYSTEMIC
HYPERTENS
ION 1-3% 3-5% 5-8% 8-10%
NO 84.8% 6.1% 3.0% 6.1%
YES 79.5% 13.1% 5.1% 2.2% 0.496
There was a non significant , but increasing risk score in those with SHT
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IMMUNOSUPPRESSION NUMBER PERCENTAGE
AZATHIOPRINE
PREDNISOLONE
65 38.22%
MMF
PREDNISOLONE
27 15.88%
CYCLOSPORINE
AZATHIOPRINE
PREDNISOLONE
3 1.76%
CYCLOSPORINE
MMF
PREDNISOLONE
4 2.35%
TACROLIMUS
AZATHIOPRINE
PREDNISOLONE
11 6.47%
TACROLIMUS
MMF
PREDNISOLONE
57 33.52%
SIROLIMUS
MMF
PREDNISOLONE
3 1.76%
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IMMUNO SUPPRESSIVE DRUGS * FRS
variable PREVALENCE p-Value
FRSGroupIMMUNO
SUPPRESSIVE
DRUGS 1-3% 3-5% 5-8% 8-10%
AZATHIOPRINE
PREDNISOLONE
85.5% 8.2% 0% 3.3%
MMF
PREDNISOLONE 73.3% 26.7% 0% 0%
CYCLOSPORINE
AZATHIOPRINE
PREDNISOLONE 100% 0% 0% 0%
CYCLOSPORINE
MMF
PREDNISOLONE
50.0% 25.0% 25.0% 0%
TACROLIMUS
AZATHIOPRINE
PREDNISOLONE 100% 0% 0% 0%
TACROLIMUS
MMF
PREDNISOLONE
77.2% 10.5% 10.5% 1.8%
SIROLIMUS
MMF
PREDNISOLONE
33.3% 0% 33.3% 33.4%
0.001
Among immunosuppressive drugs, Cyclosporine, Tacrolimus, Sirolimus.
Prednisolone and MMF significantly associated with high cardio vascular risk
score
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ECHO-FUNCTION NUMBER PERCENTAGE
DIASTOLIC
DYSFUNCTION
15 8.82%
NORMAL
FUNCTION
155 91.18%
ECHO FUNCTION * FRS
variable PREVALENCE p-Value
FRSGroupECHO
FUNCTION
1-3% 3-5% 5-8% 8-10%
NORMAL 82.6% 11.6% 5.2% 0.6%
DIASTOLIC
DYSFUNCTION 60.0% 13.3% 0% 26.7%
0.001
Cardiac dysfunction was present in 15 (8.82%) recipients, all had diastolic
dysfunction, none had systolic dysfunction and significantly associated with
cardiovascular risk score
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ECHO- LVH NUMBER PERCENTAGE
NO 131 77.06%
YES 39 22.94%
LEFT VENTRICULAR HYPERTROPHY * FRS
variable PREVALENCE p-Value
FRSGroupLVH
1-3% 3-5% 5-8% 8-10%
NO 84.0% 9.9% 3.8% 2.3%
YES 69.3% 17.9% 7.7% 5.1%
0.243
Even though statistically not significant, high risk score was observed
in patients with LVH .
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TOTAL
CHOLESTEROL
(mg/dl)
NUMBER PERCENTAGE
<200 139 81.77%
>200% 31 18.23%
TOTAL CHOLESTEROL * FRS
variable PREVALENCE p-Value
FRSGroupTOTAL
CHOLESTEROL
(mg/dl) 1-3% 3-5% 5-8% 8-10%
<200 84.9% 11.5% 2.9% 0.7%
>200 61.3% 12.9% 12.9% 12.9%
0.001
High cholesterol was significantly correlated with cardio vascular risk score
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HDL NUMBER PERCENTAGE
LOW 31 26.47%
NORMAL 128 75.29%
HIGH 11 6.47%
HDL CHOLESTEROL * FRS
variable PREVALENCE p-Value
FRSGroupHDL
CHOLESTEROL
1-3% 3-5% 5-8% 8-10%
LOW 66.6% 25.0% 6.3% 3.1%
NORMAL 72.8% 9.1% 9.1% 9.1%
HIGH 85.8% 8.7% 3.1% 2.4%
0.019
Low HDL-cholesterol was significantly correlated with cardio vascular
risk score
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TGL (mg/dl) NUMBER PERCENTAGE
<100 135 79.42%
>100 35 20.58%
LDL CHOLESTEROL * FRS
variable PREVALENCE p-Value
FRSGroupLDL
CHOLESTROL
(mg/dl) 1-3% 3-5% 5-8% 8-10%
<100 85.2% 10.4% 3.0% 1.5%
>100 62.9% 17.1% 11.4% 8.6%
0.012
High LDL- cholesterol was significantly correlated with cardio
vascular risk score
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TGL (mg/dl) NUMBER PERCENTAGE
<200 160 94.12%
>200 10 5.88%
TGL * FRS
variable PREVALENCE p-Value
FRSGroupTGL (mg/dl)
1-3% 3-5% 5-8% 8-10%
<200 82.7% 11.2% 4.3% 1.9%
>200 44.4% 22.2% 11.2% 22.2%
0.004
High TGL was significantly correlated with cardio vascular risk score
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URINE ROUTINE NUMBER PERCENTAGE
NO PROTEINURIA 139 81.76%
PROTEINURIA 31 18.24%
URINE ROUTINE * FRS
variable PREVALENCE p-Value
FRSGroupURINE
ROUTINE
1-3% 3-5% 5-8% 8-10%
NO
PROTEINURIA 86.3% 9.4% 2.9% 1.4%
PROTEINURIA 54.9% 22.6% 12.9% 9.7%
0.001
 Proteinuria was significantly associated with  cardio vascular risk score
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HEMOGLOBIN NUMBER PERCENTAGE
NORMAL 128 75.29%
PTE 15 8.82%
ANEMIA 27 15.88%
HEMOGLOBIN * FRS
variable PREVALENCE p-Value
FRSGroupHEMOGLOBIN
1-3% 3-5% 5-8% 8-10%
ANEMIA 55.5% 25.9% 14.8% 3.7%
NORMAL 86.6% 8.7% 2.4% 2.4%
PTE 75.1% 12.5% 6.3% 6.3%
0.014
Both Anaemia and post transplant erythrocytosis had  significant
cardio vascular risk score
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S. ALBUMIN
(gm/dl)
NUMBER PERCENTAGE
>3.5 127 74.71%
<3.5 43 25.29%
SERUM ALBUMIN * FRS
variable PREVALENCE p-Value
FRSGroupSERUM
ALBUMIN
(gm/dl) 1-3% 3-5% 5-8% 8-10%
>3.5 82.7% 10.2% 4.7% 2.4%
<3.5 74.5% 16.3% 4.7% 4.7%
0.679
Hypoalbuminemia  had no significant association with cardio vascular
risk score
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URIC ACID
mg/dl NUMBER PERCENTAGE
<6 131 77.05%
>6 39 22.95%
URIC ACID * FRS
variable PREVALENCE p-Value
FRSGroupURIC ACID
(mg/dl)
1-3% 3-5% 5-8% 8-10%
< 6.0 82.3% 10.8% 4.6% 2.3%
> 6.0 75.0% 15.0% 5.0% 5.0% 0.481
Influence of serum uric acid  over cardio vascular risk score not
statistically significant
67
CIMT(mm) NUMBER PERCENTAGE
<1.1 158 92.95%
?1.1 12 7.05%
CAROTID INTIMA MEDIA THICKNESS * FRS
variable PREVALENCE p-Value
FRSGroupCAROTID
INTIMA
MEDIA
THICKNESS
(mm) 1-3% 3-5% 5-8% 8-10%
<1.1 81.0% 12.0% 4.4% 2.5%
?1.1 72.7% 9.1% 9.1% 9.1%
0.001
Carotid intima media thickness had statistically significance correlation with
high cardio vascular risk score
DISCUSSION
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DISCUSSION
Cardiovascular mortality is increased in patients with chronic kidney
disease. Mortality from cardiovascular disease is10–20 times higher among
individuals treated with dialysis, as compared to general population124.1 The
incidence of cardiovascular disease in kidney transplant patients is nearly
twice that of the general population125. Even young transplant recipients (aged
35–45 years) experienced an almost 10-fold increase in cardiovascular
disease-related mortality.
Our study analyzed the relationships among traditional and transplant
specific risk factors and 10 year cardiovascular risk estimated by Framingham
risk score
Overall 170 recipients who were  on regular follow up in our
department were included in this analysis.
Total patients are divided into groups according to FRAMINGHAM
RISK SCORE to predict 10 year ABSOLUTE RISK of coronary heart disease
event. Recipients were fit into risk category of 1-3%, 3-5%, 5-8%, 8-10%
We found that 80.6% of recipients  had 1-3% of 10 year CV risk,
11.8% had 3-5% of 10 year CV risk,4.7% had 5-8% of 10 year CV risk and
2.9% had 8-10% of 10 year CV risk.
Among the traditional risk factors, age > 40years was found to be
statistically significant risk factor for 10 year CV risk. Almost 15.3% of the
total study population was >40 years of which 19.2% had  10 year CV risk of
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8-10%. This was in comparison to study done by deMattos AM et al 13 who
showed that Age > 45 years had hazard ratio of 1.57(95% CI 0.99-2.38). In
our study increased age was to be independent risk factor for higher CV risk
in the multi variate analysis
Although male gender was proposed as one of the traditional risk
factor in many studies. In our study 72.9% of the population were males and
there was no statistically significant higher CV risk in the males.
In our study, 83.5% had live related donor and 16.48% had cadaver
donors, Lentine et al 126 and deMattos AM et al13 found an increased risk of
cardiovascular events among deceased donor recipients. In our study 7.1% of
deceased donor recipients had 8-10% of 10 year CV risk.
In a  study by kasiske et al 127 showed  a markedly increased risk of
acute myocardial infarction early after transplantation, less than three months
post-surgery where as in our study cardiovascular risk was not significantly
associated with post  transplant duration though had a score of < 3%,higher
score (>3%) was observed in those with more than 4 years of post transplant
period
Renal insufficiency in renal transplant patients is a significant risk
factor for adverse cardiovascular outcomes, Serum creatinine levels  above
1.5 mg/dL (133 µmol/L) at one year post-transplant were significantly
associated with an increased risk for cardiovascular disease by  Meier-
Kriesche HU et al53 .In a second study done in 30,000 renal transplant
recipients by Abbott KC et al 54, a decreased estimated glomerular filtration
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rate at one year post-transplant correlated with increased risks of acute
coronary syndrome and heart failure .
In the Assessment of LEscol in Renal Transplantation (ALERT) trial55,
an increased serum creatinine concentration, particularly higher than 2.3
mg/dL (200 micromol/L), was strongly associated with an increased risk of
adverse cardiac events and cardiac death by Fellström B et al 56 In our study
graft dysfunction was present in 51.75% and among them 4.5% had non
significant  but increased 10 year CV risks compared to those who had normal
graft function in which only 1.2% had a risk score of 8-10%
In study by Courivaud C et al 58 , one-third of them  had metabolic
syndrome, and significant higher incidence of  cardio vascular events was
observed among patients with this syndrome, in our study prevalence of
metabolic syndrome was 31.8% of which 7.5% had a CV risk score of 8-10%
compared to 0.9% in the group without  MS
The reported incidence of NEW ONSET DIABETES AFTER
TRASPLANTATION(NODAT) in renal transplant recipients is 4% to 25%,
in our study it the incidence of NODAT was 19.41%. Ojo AO et al 9 stated
that kidney transplant recipients who developed NODAT are at 2- to 3- fold
increased risk of fatal and nonfatal CVD events. we also observed statistically
significant relation between NODAT and higher  cardiovascular risk. In our
study among the 19.41% of patients with NODAT,12.1% had a CV risk of 8-
10% compared to 0.7% in those without NODAT.
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Hypertension is present in  50% to 90% of renal transplant recipients
stated by Kasiske et al27. Though Systemic Hypertension was regarded as one
of the modifiable riskfactor of CV risks compared to general population ,renal
transplant recipients had higher prevalence of SHT and because of its
universal distribution deMattos AM et al13 did not find any correlation
between SHT and cardiovascular  risk in this study. In our study SHT was
present in 80% of the patients and there was no statistically significant
relation between SHT and higher CV risks
By Gonyea JE et al 128 and Moore R et al 129 from single- and multi-
center reports estimate that, by one year post-transplant, 80 to 90 percent of
adult recipients have total cholesterol levels >200 mg/dL , and 90 to 97
percent have LDL levels >100 mg/dL . In the study by Kasiske B et al 130,
elevated serum cholesterol  was found to be risk factor for CVevents. In our
study prevalence of   total cholesterol levels >200 mg/dL was 18.23%, LDL
levels >100 mg/dL was 20.58%, triglyceride levels>200 mg/dL was 5.88%.
All dyslipidemia was significantly associated with higher cardiovascular risk
score and serum cholesterol levels >200 mg/dL was found to be independent
risk factor for higher CV risk in the multi variate analysis.
Among the immunosuppressive groups though there are no literature
support for direct correlation between immunosuppressive drugs and  CV
risk,in our study we found higher CV risks among patients with Azathioprine
and Prednisolone combination(3.3% had risk of 8-10%) followed by
Tacrolimus, MMF, and Prednisolone combination(10.5% had risk of 5-
8%).This may be due to prevalence of other riskfactors like Tacrolimus
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induced higher incidence of NODAT and those with Azathioprine and
Prednisolone had longer post transplant duration.
On cardiac evaluation ,8.8% had diastolic dysfunction , 22.9% had
LVH and none of them had systolic dysfunction or Regional Wall Motion
Abnormality. In comparison to studies done in general population, those with
diastolic dysfunction  had statistically significant correlation with higher CV
risks.Those with LVH had non  significant higher CV risks(5.1% Vs 2.3%)
compared to those without LVH.
Prevalence of proteinuria among recipients in our study was 18.24%
which is significantly associated high cardio vascular risk score .In study by
peddi VR et al 82 Proteinuria has been reported to occur in  9% to 40% of
kidney transplant recipients, Fernandez-Fresnedo et al83 found that compared
with no proteinuria, the presence of persistent proteinuria was associated with
increased mortality, graft loss and a higher incidence of CVD
Prevalence of anemia in this study was 15.88%,where as post
transplant erythrocytosis was 8.8%,the reported prevalence among renal
transplant recipients of 20% to 80% by Afzali B et al 87, Report from
Vlahakos DV et al 131 PTE is  affecting 8 to 15 percent of kidney transplant
Recipients. In our study both anaemia and post transplant erythrocytosis
associated with higher cardio vascular risk score which was statistically
significant in compare to study by Imoagene- Oyedeji et al 92 revealed that the
cohort with anemia at 12 months, defined as a hemoglobin level of less than
12 g/dL, had inferior patient survival  and a higher proportion of
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cardiovascular deaths (6.3% versus 2.2%) compared with the nonanemic
patients
Approximately 10% of patients exhibit hypoalbuminemia at 1 year and
20% at 10 years after transplantation as reported by Guijarro C et al 94 in our
study prevalence of hypoalbuminemia  was 25.29%  and had no correlation
with cardio vascular risks.
The incidence of hyperuricemia in renal transplant recipients was 84
percent in  those  treated with cyclosporine versus 30 percent in patients
treated with azathioprine and  prednisone  reported  by Lin HY et al 103, in our
study prevalence of hyperuricemia was 22.95%,33 percent in  those  treated
with cyclosporine versus 9.3 percent in patients treated with azathioprine and
prednisone. There was no significant correlation between hyperuricemia and
high CV risks.
Among  the non invasive investigation, Carotid intima media thickness
(CIMT)was found to be independent values were significantly correlated  in
general population studied .Pierre JT et al132 , compared CIMT and
Framingham CV risk score , in his study showedThe Framingham score and
CIMT values were non-linearly related (coefficients of determination R2 were
19% and 20% in men, 28% and 29% in women, for subjects with and without
personal history of cardio-vascular disease, respectively). In our study CIMT
of ? 1.1mm was present in 7% of the recipients and among them 9.1% had
CV risk score of 8-10% compared to 2.5% in those with CIMT <1.1mm and
is statistically significant.
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In summary, univariate analysis showed significant correlation
between factors such as increased age, cadaveric graft recipients, metabolic
syndrome, NODAT, high serum cholesterol, high LDL. high TGL,diastolic
dysfunction, proteinuria, anaemia, post trasplant erythrocytosis and high
carotid intima media thickness
In multi variate regression analysis  revealed that the following risk
factors were independently associated with post-transplant  cardiovascular
disease:
INCREASING AGE
NEW ONSET DIABETES AFTER TRASPLANTATION
ELEVATED SERUM CHOLESTROL
PROTEINURIA
Similar to study done by Kasiske BL et al 13 which revealed Increasing
patient age, Diabetes Mellitus, Male sex, Cigarette smoking, Hypertension,
Elevated serum cholesterol have risk factors for CVD.
The risk factors should be managed accordingly to reduce the
cardiovascular events in the renal transplant recipients, so that the longevity
of both grtaft and the patient is enhanced.
CONCLUSION
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CONCLUSION 
According to Univariate analysis following variables were concluded as 
cardiovascular risk factors 
• INCREASED AGE, 
• CADAVERIC GRAFT RECIPIENTS,  
• METABOLIC SYNDROME, 
•  NEW ONSET DIABETES AFTER TRANSPLANTATION,  
• ELEVATED SERUM CHOLESTEROL,  
• ELEVATED LDL  CHOLESTEROL, 
•  ELEVATED TGL CHOLESTEROL, 
• DIASTOLIC DYSFUNCTION,  
• PROTEINURIA, 
• ANEMIA, 
• POST TRANSPLANT ERYTHROCYTOSIS and  
• HIGH CAROTID INTIMA MEDIA THICKNESS. 
INDEPENDENT risk factors derived from multivariate analysis were 
• INCREASING AGE 
• NEW ONSET DIABETES AFTER TRANSPLANTATION 
• ELEVATED SERUM CHOLESTEROL 
• PROTEINURIA 
• All transplant recipients should currently be considered as coronary 
heart disease risk. 
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ANNEXURES
?PROFORMA
?MASTER CHART
?ETHICAL COMMITTEE APPROVAL
FORM
PROFORMA
CARDIOVASCULAR RISKFACTORS ANALYSIS IN RENAL TRANSPLANT
RECIPIENTS
Name :
Age  :
Sex  :
Neph no:
Donor :
Date of surgery:
Post transplant duration:
DGF  :
Weight:
height :
BMI  :
Waist circumference:
NODAT:
SHT  :
Total cholesterol:
LDL :
Triglycerides(TGL):
HDL  :
Present creatinine:
Urine routine:
Hemoglobin :
Serum albumin :
S .uricacid :
Carotid intima media thickness:
ECHOFunction :
RWMA :
LVH :
EF :
Immunosuppressive drugs :
s.no name Nep. No. age sex donor p.tx.duration DGF dis.creatinine present.creat graftdysfunction BMI MS NODAT SHT Immunosuppression function RWMA LVH EF TC HDL LDL TGL FRS u.routine HCT s.albumin uricacid CIMT
1 abdulrahim 1118/09 30 M C 14 N 1.7 1.2 N U N Y N TMP nrl nil N 68 215 88 111 85 1 nrl nrl m l l
2 amthulvali 1243/09 21 F C 14 N 1.2 1.2 N nrl N N Y TMP nrl nil N 63 188 49 104 176 1 nrl nrl m l l
3 anandhan 144/07 33 M L 55 Y 1.9 2.5 Y ob1 Y N Y MP nrl nil Y 70 170 36 100 198 1 nrl nrl m l l
4 anbalagan 950/07 38 M L 44 N 1 2.2 Y ov Y N Y AP nrl nil N 65 168 46 86 60 5 pro ane l m l
5 arjunan 242/09 36 M L 30 N 1 2.2 Y U N N Y TMP nrl nil N 68 140 29 90 102 3 nrl nrl m l l
6 ashokkumar 522/07 36 M L 50 Y 2 3 Y ov Y Y Y MP nrl nil Y 66 180 54 101 125 5 nrl nrl m l l
7 anitha 562/02 26 F L 117 N 1 1 N nrl N N N AP nrl nil N 72 151 48 70 104 1 nrl nrl m l l
8 ayubkhan 270/08 24 M L 41 N 1 3 Y nrl N N Y MP nrl nil Y 70 185 41 114 108 1 pro nrl m m l
9 babu 1081/01 21 M L 114 N 0.6 1 N nrl N N Y AP anrl nil N 66 148 41 154 197 2 nrl nrl m l l
10 balaji 930/04 26 M L 82 N 1.2 1 N ob1 Y N Y AP nrl nil N 65 130 46 86 183 2 nrl nrl m l l
11 balakrishnan 1352/08 34 M C 33 Y 2.9 1.4 N ov N Y Y TMP nrl nil N 72 151 47 98 140 2 nrl ane l l l
12 balasubramani 266/03 39 M L 101 N 1.5 1.5 N nrl N N Y AP nrl nil Y 68 168 49 90 107 3 nrl nrl m l l
13 balraj 1203/09 20 M L 19 N 1 1.2 N nrl N N Y TAP nrl nil N 66 180 50 149 183 1 nrl pte m l l
14 bavanandhi 48/99 44 M L 144 N 1 2.6 Y nrl N N Y AP nrl nil Y 72 151 58 119 119 5 nrl nrl m l l
15 baskar 223/06 37 M L 62 N 1.2 2.5 Y U N N Y AP nrl nil N 65 185 47 107 107 3 nrl nrl m m l
16 buhari 002/02 33 M L 120 N 1 2 Y ov Y N Y AP nrl nil N 63 180 49 100 100 1 pro nrl m m m
17 bhuwaneshwari 429/06 25 F L 63 N 0.8 1.8 Y ov Y N N AP nrl nil N 70 140 31 120 87 5 nrl nrl l m l
18 chandrasekar 2035/05 30 M L 67 N 1 2 Y nrl N N Y AP nrl nil N 63 151 31 100 190 3 nrl nrl m l l
19 chakkaravarthy 604/97 58 M L 341 N 1 1.6 Y ov N N N AP nrl nil N 70 185 39 98 198 3 nrl ane m l l
20 chengamuthu 558/08 29 M L 36 N 1 2.2 Y nrl N N N AP nrl nil N 65 180 47 80 256 1 nrl nrl m l l
21 das prakash 49/09 37 M C 19 N 1.2 2 N nrl Y N Y TMP nrl nil N 68 151 50 101 119 5 pro nrl m m l
22 dheenadayalan 569/09 37 M L 23 N 1.4 2 Y nrl N N Y TMP nrl nil N 66 151 58 70 107 3 pro nrl m m l
23 devi 332/09 30 F C 18 N 1.2 2 Y U N N Y TMP nrl nil N 72 185 47 114 183 1 nrl ane m l l
24 devaraj 902/09 48 F C 22 N more 1.4 N nrl Y Y Y TMP anrl nil Y 65 220 49 124 140 3 pro nrl l m l
25 devaki 111/09 23 F L 29 N 1.5 more N U N N Y AP nrl nil N 70 174 36 88 120 3 nrl nrl m l l
26 devika 442/10 42 F L 17 N 0.9 0.9 N nrl N N Y MP nrl nil N 65 188 38 76 120 5 pro nrl l l l
27 dhanalakshmi 261/05 40 F L 22 N 1 1 N ov N N N AP nrl nil N 68 180 58 120 119 5 nrl nrl m l l
28 dyson 239/07 20 F L 53 N 1 3 Y nrl N N N TMP nrl nil N 66 151 47 68 107 1 nrl nrl m l l
29 elavarasan 166/09 23 M C 20 N 1 1.7 N nrl Y Y Y TMP nrl nil N 70 185 39 90 100 9 pro nrl m l l
30 elumalai.k 84/02 28 M L 114 N 1 3 Y U N N Y AP nrl nil N 60 156 36 101 87 2 nrl ane m m l
31 elumalai.r 79/07 22 M L 248 N 0.8 1.5 N ov N N Y AP nrl nil N 66 148 55 70 78 2 nrl nrl m l l
32 fathima 928/09 26 F L 17 N 0.9 2.6 Y U N N Y TAP nrl nil N 72 215 39 114 154 2 nrl ane l l l
33 gandhi 196/06 36 M L 54 N 1 1.7 N nrl Y Y N AP nrl nil N 58 178 48 154 168 1 pro nrl m l l
34 giri 949/10 23 M L 19 N 1.3 2.5 Y U Y Y Y TMP nrl nil N 65 180 45 105 107 8 pro ane m m l
35 gomathi 1037/02 37 F L 99 N 1 2 N nrl N N N AP nrl nil N 68 151 50 76 100 1 nrl nrl m l l
36 gopal 1106/09 36 M L 24 N 1.4 3 Y ov Y Y Y CMP nrl nil Y 66 185 58 99 87 5 pro ane l l l
37 gopikrishnan 1185/08 42 M C 26 Y 1.4 1.4 N nrl Y N Y TMP nrl nil N 70 210 37 126 158 8 nrl nrl m l l
38 jayakumar 2746/09 31 M C 24 N 1.2 1.4 N U N N N TMP nrl nil N 65 144 49 74 112 1 nrl pte m m l
39 jeyaprakasham 1235/09 32 M L 19 N 0.8 1.6 Y ov Y Y Y TMP nrl nil N 68 201 52 93 126 5 nrl nrl m l l
40 jeevarathinam 355/05 28 M L 75 N 1.3 2 Y nrl N Y Y AP nrl nil N 66 218 46 73 124 1 nrl ane m l l
41 julian 773/09 42 M L 25 N 1 2.2 Y nrl Y Y N SMP anrl nil Y 66 180 40 110 134 10 pro pte l m l
42 kamaraj 227/09 27 M L 31 N 1 2 Y nrl N N Y TMP nrl nil N 70 151 47 80 102 1 nrl nrl m l l
43 karthikeyan 22/06 34 M L 29 N 1.4 2.6 Y U Y Y Y TMP nrl nil N 60 185 40 61 212 5 pro ane m l l
44 kasirajan 119/06 32 M L 67 N 1 2 Y nrl N N Y AP nrl nil Y 68 176 56 78 123 1 nrl nrl m l l
45 kathiravan 114/06 43 M L 67 N more 1.3 N ov Y N Y MP nrl nil N 65 154 40 110 107 5 nrl pte l l l
46 kathirvel 662/07 31 M L 20 Y 1.7 1.7 Y nrl Y Y Y CAP nrl nil N 62 223 39 145 100 1 nrl pte m l m
47 kumar.w 94/10 33 M L 17 N 0.7 1.7 N nrl N N Y TMP nrl nil N 66 180 36 54 87 6 nrl nrl l m l
48 kumar.c 1312/09 33 M C 16 N 1.2 2 Y U N N N TMP nrl nil N 70 205 45 125 198 1 nrl nrl l m l
49 kumaresan 1103/02 32 M L 99 N 1.5 1.5 Y nrl N N Y AP nrl nil N 60 164 40 101 240 7 nrl ane l l l
50 kumaravel 118/06 29 M L 65 N 1 1.5 N nrl N N Y MP nrl nil N 65 180 52 70 130 1 nrl nrl m l l
51 lakshmi 756/07 50 F L 42 Y 2.7 1.5 N nrl N Y Y MP nrl nil N 63 151 48 114 119 5 nrl ane m l l
52 logeshwaran 97/07 28 M L 54 N 1 1.6 Y U N N Y MP nrl nil N 70 185 32 154 107 1 nrl nrl m l l
53 lillythresa 1373/08 31 F C 33 Y 1.8 1.6 N ob1 Y N Y TMP nrl nil N 65 152 55 77 168 1 nrl nrl m l l
54 madanagopal 221/06 42 M L 59 N 1 1.5 N nrl N N Y AP nrl nil Y 68 180 50 119 85 3 nrl nrl l l l
55 malathi 349/04 27 F L 84 N 1 1 N nrl N N Y AP nrl nil N 66 151 31 107 146 1 nrl nrl l l l
56 manikandan 1337/07 25 M L 45 N 1 1 N nrl Y N Y AP nrl nil N 72 185 39 100 183 1 nrl nrl m l l
57 mary 265/04 26 F L 89 N 1.2 1.3 N nrl N N Y AP nrl nil N 65 201 47 120 126 1 nrl nrl m l l
58 marimuthu 617/02 35 M L 120 N more 2.2 Y nrl Y Y Y MP nrl nil N 68 218 31 96 124 5 nrl nrl m l m
59 manjunathan 1167/02 28 M L 95 N 1.2 3 Y U N N N AP nrl nil N 66 180 68 70 134 1 pro ane m l l
60 menaga 464/06 28 F L 65 N 1 1.7 Y nrl N N Y AP nrl nil N 70 151 55 47 102 1 nrl nrl m m l
61 menaha 769/09 52 F L 27 Y 1.6 1.6 N nrl Y Y Y CMP nrl nil Y 65 185 40 79 107 8 nrl ane m l l
62 mercyannamary 496/07 47 F L 51 Y 1.7 2.2 Y ob1 Y Y Y MP nrl nil Y 68 170 36 88 100 5 pro ane m m l
63 mohaan 1160/07 35 M L 47 N 1 2 Y nrl N N Y MP nrl nil N 66 126 56 80 87 1 nrl nrl l l l
64 mohan 1308/08 40 M L 35 N more 1.6 N ov Y N Y TAP nrl nil N 58 174 32 54 200 8 nrl nrl l l l
65 murali 1368/02 27 M L 106 N more 1.8 Y nrl Y Y Y AP nrl nil Y 62 188 48 101 134 1 nrl nrl m m l
66 murugesan 1106/06 27 M L 58 N 1.3 3 Y nrl N N Y MP nrl nil N 66 170 46 70 110 1 nrl pte m l m
67 nagaraj 316/07 36 M L 46 N more 1.6 N nrl Y N Y MP nrl nil N 63 126 58 116 126 3 nrl nrl m l l
68 nainarmohamed 2000/05 31 M L 66 N 1 1.7 Y nrl N N Y MP nrl nil Y 70 170 47 100 124 1 pro nrl l l l
69 nazirali 1242/09 27 M C 15 Y 2 1.6 N ov Y N Y TMP nrl nil N 65 126 49 70 134 1 nrl nrl m l l
70 navaneetham 296/97 37 F L 164 N 1 1.4 N nrl N N N AP nrl nil N 68 172 31 119 102 3 nrl nrl m l l
71 nirmala 1221/07 36 F C 18 Y 1.3 2 Y nrl N N N TMP nrl nil N 66 168 31 107 230 1 pro ane m m l
72 palani 467/09 30 M L 30 N 1.5 2.5 Y nrl N N Y MP nrl nil N 72 174 39 100 140 1 nrl nrl l l l
73 poonguzali 691/02 29 F L 130 N 0.8 2.8 Y nrl N N N AP nrl nil N 66 188 47 120 158 1 pro nrl m l l
74 prasanth 17/10 30 M L 20 N 1.4 1.6 N nrl Y N Y TMP nrl nil N 70 220 55 134 173 1 nrl nrl m l m
75 prema 1433/08 36 F C 22 N more 1.2 N ob1 Y Y Y TMP nrl nil Y 65 190 68 132 124 8 pro ane l l m
76 priya 758/00 33 F L 130 N 0.6 1.5 Y ov N N N AP nrl nil N 68 143 44 90 132 1 nrl nrl m l l
77 raja 1174/06 28 M L 52 N 1 7.5 Y U N N Y AP nrl nil N 66 140 48 112 160 1 nrl nrl m m l
78 rajkamal 525/08 24 M L 40 Y 1.7 2.5 Y nrl N N Y AP nrl nil N 68 151 32 101 100 6 pro ane m m l
79 rajmohan 501/06 39 M L 63 Y 1.8 10.5 Y nrl N N Y MP nrl nil Y 65 185 47 70 102 3 nrl nrl l m l
80 raman 566/05 30 M L 72 N 1 3 Y nrl N N Y MP nrl nil N 58 180 49 114 80 1 pro ane m l l
81 ramachandran 1130/07 41 M L 46 Y 2.8 3 Y nrl N N N AP nrl nil N 62 151 36 154 109 3 nrl nrl l l l
82 ramamoorthy 382/04 60 M L 88 Y 1.8 3 Y nrl Y Y Y AP anrl nil N 66 180 46 130 71 10 pro nrl m l l
83 ramaamoorthy 420/08 42 M L 40 Y 1.6 1.6 N ov Y N Y MP nrl nil N 63 151 58 79 90 3 nrl nrl m l l
84 ramesh 776/04 33 M L 84 Y 3.2 2 Y U N N Y MP nrl nil Y 70 185 47 88 190 1 nrl nrl m l l
85 ramesh 1308/07 23 M L 44 Y 1 2.2 Y nrl N N Y MP nrl nil N 62 148 49 80 198 1 nrl nrl l l l
86 ramesh 999/09 26 M L 22 Y 1.6 2.2 Y nrl N N Y TMP nrl nil Y 65 166 31 54 200 1 nrl nrl m l l
87 ramesh 1075/10 33 M L 13 N 1.5 1.7 N nrl N N Y TMP nrl nil N 68 181 31 101 108 1 nrl nrl l m m
88 ravi 30/07 20 M L 48 Y 1.9 1.5 N nrl N N N AP nrl nil N 70 140 39 70 148 1 nrl nrl m l l
89 ravi 573/07 37 M L 50 N 1 1.8 Y nrl N N Y MP nrl nil N 65 151 47 101 117 3 nrl nrl m l l
90 ravichandran 173/04 37 M L 90 N 1.4 3.5 Y nrl N N Y MP nrl nil N 68 185 55 98 96 8 nrl nrl m l l
91 renuga 001/07 38 F C 29 N 1.2 1 N nrl N N Y TMP nrl nil N 66 180 68 81 81 3 nrl nrl m l l
92 revathy 756/09 26 F C 22 N 1 1 N nrl Y N Y TMP nrl nil N 63 151 44 89 67 1 nrl nrl m m l
93 riyaz ali 806/09 26 M C 20 N 1.3 1.4 N nrl Y Y Y TMP nrl nil N 70 158 48 117 138 1 nrl pte m l l
94 sabeetha 1174/07 30 F L 39 N 1 1.6 N nrl N N Y MP nrl nil N 65 201 32 98 156 1 nrl nrl l l l
95 sadhasivam 812/07 34 M L 50 N 1.3 1.8 Y nrl N N Y CMP anrl nil N 68 218 31 98 111 7 nrl nrl l l l
96 sakthivel 572/05 31 M L 71 N 1.4 1.6 N nrl N N Y AP nrl nil N 66 180 68 81 198 1 nrl nrl m m l
97 sakthivel 859/04 40 M L 84 N more 1.2 N ov Y Y Y AP anrl nil N 72 151 34 67 230 3 pro nrl l l l
98 samregis 1105/06 26 M L 59 N 1 2 Y nrl N N Y SMP nrl nil N 70 185 46 101 80 1 nrl nrl m l l
99 saranya 448/05 21 F L 74 N 1 2.2 Y nrl N N Y TMP nrl nil N 65 180 47 70 112 1 nrl nrl m l l
100 sarasu 361/07 36 F L 53 N 1 2 Y nrl Y N Y MP nrl nil N 68 151 49 114 232 3 nrl nrl m l l
101 sathishkumar 1273/06 25 M L 57 N 1 3 Y ob1 Y N Y TMP nrl nil Y 66 185 31 154 146 1 pro nrl l m m
102 santhanakumar 717/07 27 M L 47 N 1.5 3 Y nrl N N Y MP nrl nil N 68 160 31 137 248 1 nrl nrl m l l
103 sathya 255/10 30 F L 42 N 1 1.3 N nrl N Y Y AP nrl nil N 66 180 39 79 120 1 nrl nrl m l l
104 selvaraj 846/07 62 M L 238 N 1 2 Y nrl N Y N CP nrl nil N 63 151 47 88 119 10 nrl ane m l m
105 senthilraja 666/02 31 M L 105 N more 1.7 Y ov Y Y Y AP nrl nil N 63 185 48 80 107 1 nrl nrl m l l
106 seshadari 425/04 46 M L 89 Y 1.8 2.5 Y nrl N N Y MP nrl nil Y 70 142 56 54 100 5 nrl nrl m m l
107 shankar 5049/89 53 M L 269 N 1.4 2.8 Y nrl N N Y MP nrl nil N 65 140 36 101 87 5 nrl nrl l m l
108 shankar 388/09 33 M L 18 N 1 1.4 N nrl N Y Y TMP anrl nil N 68 151 38 70 140 1 nrl nrl m l m
109 shanmugam 940/07 30 M L 47 N 1 1.2 N U Y Pre dm Y AP anrl nil Y 66 185 42 90 120 1 nrl nrl m l l
110 sharbudeen 725/07 29 M L 49 N 1 1.7 Y nrl Y N Y AP nrl nil Y 72 180 46 73 120 1 nrl nrl m l l
111 simsone 905/06 30 M L 65 N 1 2 Y nrl Y N Y AP nrl nil N 66 151 58 100 119 1 nrl nrl l l l
112 srinivasan 784/07 28 M L 48 Y 1.5 2 Y U N N Y AP nrl nil N 66 180 47 110 107 1 nrl nrl m l l
113 subramanian 1313/04 47 M L 78 N 1 2.2 Y nrl N N Y AP nrl nil N 65 162 49 95 100 5 nrl ane l l l
114 subramanian 341/09 49 M C 24 N 1 1.2 N U Y Y Y TMP nrl nil N 58 201 48 124 87 9 nrl nrl m l l
115 syedmusthafa 68/06 28 M L 64 Y 1.5 2 Y nrl N N Y AP nrl nil N 65 218 32 119 90 1 nrl nrl m l l
116 tamilarasan 1334/06 25 M L 57 N 1 1.5 Y nrl N N Y AP nrl nil N 70 180 55 107 120 1 nrl nrl m l l
117 thagira 643/03 30 F L 95 N 1 1 N ov N N N AP nrl nil N 65 151 46 100 119 1 nrl nrl m l l
118 thangaraj 1195/08 34 M L 35 N 1.3 2 Y nrl N N Y MP nrl nil N 68 185 39 120 107 3 nrl nrl m l l
119 thilagam 1314/09 31 F L 21 N 1.3 1.5 N ob1 Y N Y CAP nrl nil Y 66 146 55 110 100 1 pro ane m l l
120 thirunavukarasu 215/02 42 M L 96 Y 1 1.8 Y nrl N N Y MP nrl nil N 63 176 46 100 87 3 nrl nrl m l m
121 thulasi 67/09 21 F L 30 N 1 1.2 N nrl N N Y TAP nrl nil N 70 153 48 87 117 1 nrl nrl m l l
122 umamaheswaran 840/03 34 M L 128 N 0.8 1 N nrl Y Y N AP nrl nil N 65 126 32 117 98 5 nrl nrl m l l
123 usha 351/05 19 F L 76 N 1 1 N nrl N N N AP nrl nil N 68 201 55 75 81 1 nrl nrl l l l
124 varadhan 420/00 39 M L 124 N 1 2 N nrl N N Y AP nrl nil Y 66 218 45 100 67 5 nrl nrl m l l
125 venkatash 169/09 31 M L 31 N 0.9 1.5 Y U Y Pre dm N TMP nrl nil N 72 180 31 98 138 8 nrl pte l l l
126 vijaya 896/04 47 F L 86 N 1 1.5 N ov N N Y AP nrl nil N 68 151 39 81 100 3 nrl ane m l l
127 vijayakumar 587/02 36 M L 67 N 1 2.3 Y nrl Y Y Y SMP nrl nil N 66 185 47 67 111 8 pro ane m m l
128 vijayalakshmi 370/06 42 F L 64 N 1 1 N ov Y N N MP nrl nil N 65 180 31 79 198 3 nrl nrl m l l
129 vijayapandian 1071/08 31 M L 35 N 1 2.7 Y nrl Y N Y CMP nrl nil Y 68 151 68 88 80 1 pro ane l l l
130 vishwanathan 421/04 39 M L 86 Y 1.8 2.7 Y nrl N N N AP nrl nil N 70 185 46 80 88 3 nrl nrl m l l
131 vinayagam 943/01 37 M L 104 N 1 1.3 N nrl N N N AP nrl nil N 65 184 58 54 124 3 nrl nrl m l l
132 vinothkumar 1247/06 21 M L 16 Y 1.7 1.5 N nrl Y N Y TAP nrl nil Y 68 146 47 101 232 1 nrl nrl m l l
133 vivekanandan 572/09 21 M L 24 N 1 1.2 N U N N Y CAP nrl nil N 66 189 49 70 146 1 nrl nrl l l l
134 rajasekaran 191/11 30 M L 4 N 0.9 1 N nrl N N Y TMP nrl nil N 68 132 31 40 85 1 nrl nrl m m l
135 hari 803/11 30 M L 1 N 1 1 N nrl N N N TMP nrl nil N 66 154 31 111 176 1 nrl nrl l m l
136 pandian 490/11 26 M L 1 N 1 1 N nrl N N Y TAP nrl nil Y 65 215 39 104 190 1 nrl nrl l l l
137 perumal 460/10 25 M C 6 N 0.8 1.2 N U N N Y TMP nrl nil N 68 188 47 100 198 1 nrl nrl l l l
138 syedmoosa 775/11 25 M L 1 N 1 1 N nrl N N Y TMP nrl nil N 66 170 55 86 102 1 nrl nrl m l l
139 seethalakshmi 1246/10 36 F L 9 N 0.8 1 N ov N N N TMP nrl nil N 68 154 68 90 366 3 nrl pte l l l
140 kalpana 887/10 25 F L 8 Y 1.7 2 Y nrl N N Y TMP nrl nil Y 65 140 44 101 198 1 nrl pte m m l
141 jayaprakash 855/10 26 M L 13 N 1 1 Y U N N Y TAP anrl nil N 63 140 48 70 190 1 nrl nrl m m l
142 megala 787/11 32 F L 2 N 1 1.2 N nrl N N Y TAP nrl nil N 70 151 32 114 183 1 nrl pte m l l
143 suresh 816/10 35 M L 11 N 1 1 N ov N N Y TMP nrl nil Y 65 185 38 154 140 3 nrl nrl m m l
144 sulaiman 630/10 29 M L 11 N 0.9 1 N ov N N Y TMP nrl nil Y 68 180 46 79 190 1 nrl pte m l l
145 ramamoorthy 610/06 35 M L 61 N 1 1.4 N nrl N N Y AP nrl nil N 66 151 47 88 198 3 nrl nrl m l l
146 babu 934/10 37 M L 8 N 1 1.2 N nrl N Y Y TMP anrl nil N 72 180 49 80 119 5 nrl pte m l l
147 narasingam 1367/09 22 M C 12 Y 1.2 1.4 N nrl N N Y TMP anrl nil Y 55 151 31 54 107 1 nrl nrl m m l
148 mohamedrafi 717/10 22 M L 10 N 0.9 1.2 N nrl N N Y TMP nrl nil N 68 185 47 101 100 1 nrl pte l m l
149 murugan 1241/10 39 M C 3 N 1 1.4 N nrl N N Y TMP nrl nil Y 70 178 49 70 87 5 nrl nrl m m l
150 poonkodi 304/10 45 F C 8 N 0.9 1 N ov Y Y Y TMP nrl nil Y 65 188 31 100 120 8 pro nrl m l l
151 vinothkumar 1573/10 20 M L 3 N 1 1.7 Y U N N N TAP nrl nil N 68 202 31 120 119 1 nrl nrl m m l
152 sajeevan 702/10 32 M C 7 N 1 2 Y U N Y N TMP anrl nil N 66 211 39 79 107 5 pro ane l l l
153 antonyjaganraj 1241/10 29 M L 11 Y 1 1 N ov Y N Y TMP nrl nil Y 65 156 47 88 100 1 nrl nrl m l l
154 dhanalakshmi 1054/10 35 F L 10 N 0.9 1 N ov Y Y N TAP nrl nil N 68 200 34 80 120 3 nrl nrl m l l
155 rameshkumar 816/04 25 M L 83 N 1 2 Y nrl N N Y AP nrl nil Y 66 166 47 54 119 2 nrl nrl m l l
156 rajeshwari 545/10 32 F L 10 N 1 1 Y nrl N N Y TAP nrl nil N 68 178 49 101 107 2 nrl nrl m m l
157 saraswathy 1322/10 29 F L 5 N 1 1.2 N ov N N Y TMP nrl nil N 60 215 38 70 100 2 nrl nrl m l l
158 alli 752/10 45 F C 4 N 1 1 N ov Y N Y TMP nrl nil N 62 188 46 120 120 3 nrl nrl m l l
159 arumugam 1105/09 32 M C 12 N 1 2 Y U N N N TMP anrl nil Y 58 170 58 108 120 1 pro ane l m l
160 sathishkannan 1186/10 35 M L 7 N 0.8 1.7 Y nrl N N Y TMP anrl nil N 66 200 47 110 140 1 nrl nrl m m l
161 suresh 126/11 35 M L 2 N 1 1.7 Y ov N N Y TMP nrl nil N 64 140 49 79 183 4 nrl pte m l m
162 kavitha 571/11 28 F L 4 Y 1 1 N ov N N Y TMP nrl nil Y 68 151 31 88 190 1 nrl nrl l l l
163 periyasamy 1353/08 28 M C 12 N 1 2 Y U N N Y TMP nrl nil Y 66 185 31 80 198 1 pro nrl l l l
164 venkatesan 334/03 30 M L 96 N 1 2.5 Y nrl N N Y AP nrl nil Y 70 180 39 54 268 1 nrl nrl m l l
165 kesavajothi 101/03 35 M L 96 N 1 1.4 N nrl N N Y AP nrl nil N 65 151 47 101 120 3 nrl nrl m l l
166 ranjithkumar 37/05 33 M L 72 N 1 1.8 Y nrl N N Y AP nrl nil N 68 185 55 70 119 3 nrl nrl m l l
167 geetha 287/11 23 F L 3 N 0.8 1 N nrl N N Y TMP nrl nil N 66 162 68 114 107 4 nrl nrl m l l
168 stephen 1367/04 48 M L 93 N 1 1.5 N U N N Y AP nrl nil N 68 201 44 154 100 1 nrl nrl m l l
169 abdulmunaf 9918/96 53 M C 188 N 0.9 2 Y nrl Y N Y AP anrl nil N 50 218 48 130 190 10 nrl nrl m l l
170 suja 818/09 26 F C 10 N 1 1.7 Y U N N Y TMP nrl nil N 70 180 32 89 198 1 nrl pte m l l
years M=male L=live months N=no,Y=yes mg/dl mg/dl N=no,Y=yesU=under weight N=no,Y=yes A=azathioprine nrl=normal nil=no N=no,Y=yes % mg/dl mg/dl mg/dl mg/dl % nrl=normal nrl=normal m=>3.5gm m=>6mg m=?1.1mm
F=femaleC=cadaver nrl=normal P=prednisolone anrl=abnormal pro=proteinuria ane=anemia l=<3.5gm l=<6mg l=<1.1mm
ov=over weight M=MMF pte=post transp
ob1=obesity1 T=tacrolimus lanteryrhtrocytosis
C=cyclosporine
S=sirolimus
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